Information
References
Contents
Download
[1]D. Claar, T. V. Hartert and R. S. Peebles, Jr.: The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med 9, 55-72 (2015)
[2]T. Shimizu: Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 49, 123-50 (2009)
[3]R. C. Harris and M. Z. Zhang: Cyclooxygenase metabolites in the kidney. Compr Physiol 1, 1729-58 (2011)
[4]V. Capra, M. Back, S. S. Barbieri, M. Camera, E. Tremoli and G. E. Rovati: Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 33, 364-438 (2013)
[5]A. R. Morrison and N. Pascoe: Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proc Natl Acad Sci U S A 78, 7375-8 (1981)
[6]E. H. Oliw, J. A. Lawson, A. R. Brash and J. A. Oates: Arachidonic acid metabolism in rabbit renal cortex. Formation of two novel dihydroxyeicosatrienoic acids. J Biol Chem 256, 9924-31 (1981)
[7]W. B. Campbell, D. Gebremedhin, P. F. Pratt and D. R. Harder: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78, 415-23 (1996)
[8]J. C. McGiff and J. Quilley: 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol 277, R607-23 (1999)
[9]M. Rahman, J. T. Wright, Jr. and J. G. Douglas: The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Am J Hypertens 10, 356-65 (1997)
[10]R. J. Roman and M. Alonso-Galicia: P-450 Eicosanoids: A novel Signaling Pathway Regulating Renal Function. News Physiol Sci 14, 238-242 (1999)
[11]F. Fan, Y. Muroya and R. J. Roman: Cytochrome P450 eicosanoids in hypertension and renal disease. Curr Opin Nephrol Hypertens 24, 37-46 (2015)
[12]D. R. Harder, N. J. Alkayed, A. R. Lange, D. Gebremedhin and R. J. Roman: Functional hyperemia in the brain: hypothesis for astrocyte-derived vasodilator metabolites. Stroke 29, 229-34 (1998)
[13]D. R. Harder, D. Gebremedhin, J. Narayanan, C. Jefcoat, J. R. Falck, W. B. Campbell and R. Roman: Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol 266, H2098-2107 (1994)
[14]E. Hill and R. C. Murphy: Quantitation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) produced by human polymorphonuclear leukocytes using electron capture ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 21, 249-53 (1992)
[15]J. D. Imig, A. P. Zou, D. E. Stec, D. R. Harder, J. R. Falck and R. J. Roman: Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol 270, R217-27 (1996)
[16]O. Ito, Y. Nakamura, L. Tan, T. Ishizuka, Y. Sasaki, N. Minami, M. Kanazawa, S. Ito, H. Sasano and M. Kohzuki: Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol Cell Biochem 284, 141-8 (2006)
[17]R. J. Roman, K. G. Maier, C. W. Sun, D. R. Harder and M. Alonso-Galicia: Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 27, 855-65 (2000)
[18]D. Zhu, R. M. Effros, D. R. Harder, R. J. Roman and E. R. Jacobs: Tissue sources of cytochrome P4504A and 20-HETE synthesis in rabbit lungs. Am J Respir Cell Mol Biol 19, 121-8 (1998)
[19]K. Node, Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D. C. Zeldin and J. K. Liao: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-9 (1999)
[20]M. M. Muthalif, I. F. Benter, N. Karzoun, S. Fatima, J. Harper, M. R. Uddin and K. U. Malik: 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci U S A 95, 12701-6 (1998)
[21]M. R. Uddin, M. M. Muthalif, N. A. Karzoun, I. F. Benter and K. U. Malik: Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension 31, 242-7 (1998)
[22]F. Lin, A. Rios, J. R. Falck, Y. Belosludtsev and M. L. Schwartzman: 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol 269, F806-16 (1995)
[23]L. D. Orozco, H. Liu, E. Perkins, D. A. Johnson, B. B. Chen, F. Fan, R. C. Baker and R. J. Roman: 20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries. J Pharmacol Exp Ther 346, 67-74 (2013)
[24]A. M. Guo, A. S. Arbab, J. R. Falck, P. Chen, P. A. Edwards, R. J. Roman and A. G. Scicli: Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther 321, 18-27 (2007)
[25]R. J. Roman: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82, 131-85 (2002)
[26]J. D. Imig: Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat 104-105, 2-7 (2013)
[27]J. M. Williams, F. Fan, S. Murphy, C. Schreck, J. Lazar, H. J. Jacob and R. J. Roman: Role of 20-HETE in the antihypertensive effect of transfer of chromosome 5 from Brown Norway to Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 302, R1209-18 (2012)
[28]J. M. Lasker, W. B. Chen, I. Wolf, B. P. Bloswick, P. D. Wilson and P. K. Powell: Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 275, 4118-26 (2000)
[29]P. K. Powell, I. Wolf, R. Jin and J. M. Lasker: Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285, 1327-36 (1998)
[30]V. Hirani, A. Yarovoy, A. Kozeska, R. P. Magnusson and J. M. Lasker: Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies. Arch Biochem Biophys 478, 59-68 (2008)
[31]J. V. Gainer, A. Bellamine, E. P. Dawson, K. E. Womble, S. W. Grant, Y. Wang, L. A. Cupples, C. Y. Guo, S. Demissie, C. J. O’Donnell, N. J. Brown, M. R. Waterman and J. H. Capdevila: Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111, 63-9 (2005)
[32]Y. Kikuta, E. Kusunose, K. Endo, S. Yamamoto, K. Sogawa, Y. Fujii-Kuriyama and M. Kusunose: A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase. J Biol Chem 268, 9376-80 (1993)
[33]F. Fan, A. M. Geurts, S. R. Murphy, M. R. Pabbidi, H. J. Jacob and R. J. Roman: Impaired myogenic response and autoregulation of cerebral blood flow is rescued in CYP4A1 transgenic Dahl salt-sensitive rat. Am J Physiol Regul Integr Comp Physiol 308, R379-90 (2015)
[34]J. P. Hardwick, B. J. Song, E. Huberman and F. J. Gonzalez: Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid omega-hydroxylase (cytochrome P-450 LA omega). Identification of a new cytochrome P-450 gene family. J Biol Chem 262, 801-10 (1987)
[35]X. Nguyen, M. H. Wang, K. M. Reddy, J. R. Falck and M. L. Schwartzman: Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol 276, R1691-700 (1999)
[36]H. Kawashima, E. Kusunose, C. M. Thompson and H. W. Strobel: Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 347, 148-54 (1997)
[37]H. Kawashima and H. W. Strobel: cDNA cloning of three new forms of rat brain cytochrome P450 belonging to the CYP4F subfamily. Biochem Biophys Res Commun 217, 1137-44 (1995)
[38]Y. Kikuta, E. Kusunose, M. Ito and M. Kusunose: Purification and characterization of recombinant rat hepatic CYP4F1. Arch Biochem Biophys 369, 193-6 (1999)
[39]F. Xu, J. R. Falck, P. R. Ortiz de Montellano and D. L. Kroetz: Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther 308, 887-95 (2004)
[40]J. Bylund, A. G. Harder, K. G. Maier, R. J. Roman and D. R. Harder: Leukotriene B4 omega-side chain hydroxylation by CYP4F5 and CYP4F6. Arch Biochem Biophys 412, 34-41 (2003)
[41]V. R. Holla, F. Adas, J. D. Imig, X. Zhao, E. Price, Jr., N. Olsen, W. J. Kovacs, M. A. Magnuson, D. S. Keeney, M. D. Breyer, J. R. Falck, M. R. Waterman and J. H. Capdevila: Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A 98, 5211-6 (2001)
[42]D. N. Muller, C. Schmidt, E. Barbosa-Sicard, M. Wellner, V. Gross, H. Hercule, M. Markovic, H. Honeck, F. C. Luft and W. H. Schunck: Mouse Cyp4a isoforms: enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403, 109-18 (2007)
[43]M. L. Schwartzman, J. R. Falck, P. Yadagiri and B. Escalante: Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J Biol Chem 264, 11658-62 (1989)
[44]B. Escalante, W. C. Sessa, J. R. Falck, P. Yadagiri and M. L. Schwartzman: Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J Pharmacol Exp Ther 248, 229-32 (1989)
[45]X. H. Collins, S. D. Harmon, T. L. Kaduce, K. B. Berst, X. Fang, S. A. Moore, T. V. Raju, J. R. Falck, N. L. Weintraub, G. Duester, B. V. Plapp and A. A. Spector: Omega-oxidation of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4. J Biol Chem 280, 33157-64 (2005)
[46]Y. B. Jarrar, E. Y. Cha, K. A. Seo, J. L. Ghim, H. J. Kim, D. H. Kim, S. J. Lee and J. G. Shin: Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. J Lipid Res 55, 2334-42 (2014)
[47]K. M. Knights, A. Rowland and J. O. Miners: Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 76, 587-602 (2013)
[48]A. W. Dreisbach, S. V. Smith, P. B. Kyle, M. Ramaiah, M. Amenuke, M. R. Garrett, S. T. Lirette, M. E. Griswold and R. J. Roman: Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease. Prostaglandins Other Lipid Mediat 113-115, 45-51 (2014)
[49]J. S. Marji, M. H. Wang and M. Laniado-Schwartzman: Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries. Am J Physiol Renal Physiol 283, F60-7 (2002)
[50]M. Renic, J. A. Klaus, T. Omura, N. Kawashima, M. Onishi, N. Miyata, R. C. Koehler, D. R. Harder and R. J. Roman: Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 29, 629-39 (2009)
[51]M. A. Carroll, R. Kemp, M. K. Cheng and J. C. McGiff: Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med Sci Monit 7, 567-72 (2001)
[52]F. Fan, C. W. Sun, K. G. Maier, J. M. Williams, M. R. Pabbidi, S. P. Didion, J. R. Falck, J. Zhuo and R. J. Roman: 20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K+ channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels. PLoS One 8, e82482 (2013)
[53]E. K. Birks, M. Bousamra, K. Presberg, J. A. Marsh, R. M. Effros and E. R. Jacobs: Human pulmonary arteries dilate to 20-HETE, an endogenous eicosanoid of lung tissue. Am J Physiol 272, L823-9 (1997)
[54]A. Yaghi, C. D. Webb, J. A. Scott, S. Mehta, J. R. Bend and D. G. McCormack: Cytochrome P450 metabolites of arachidonic acid but not cyclooxygenase-2 metabolites contribute to the pulmonary vascular hyporeactivity in rats with acute Pseudomonas pneumonia. J Pharmacol Exp Ther 297, 479-88 (2001)
[55]J. S. Wang, H. Singh, F. Zhang, T. Ishizuka, H. Deng, R. Kemp, M. S. Wolin, T. H. Hintze, N. G. Abraham, A. Nasjletti and M. Laniado-Schwartzman: Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 98, 962-9 (2006)
[56]K. Inoue, K. Sodhi, N. Puri, K. H. Gotlinger, J. Cao, R. Rezzani, J. R. Falck, N. G. Abraham and M. Laniado-Schwartzman: Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am J Physiol Renal Physiol 297, F875-84 (2009)
[57]H. Singh, J. Cheng, H. Deng, R. Kemp, T. Ishizuka, A. Nasjletti and M. L. Schwartzman: Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50, 123-9 (2007)
[58]C. C. Wu, J. Cheng, F. F. Zhang, K. H. Gotlinger, M. Kelkar, Y. Zhang, J. L. Jat, J. R. Falck and M. L. Schwartzman: Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: role of inhibitor of kappaB Kinase. Hypertension 57, 788-94 (2011)
[59]H. Singh and M. L. Schwartzman: Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep 60, 29-37 (2008)
[60]M. Renic, S. N. Kumar, D. Gebremedhin, M. A. Florence, N. Z. Gerges, J. R. Falck, D. R. Harder and R. J. Roman: Protective effect of 20-HETE inhibition in a model of oxygen-glucose deprivation in hippocampal slice cultures. Am J Physiol Heart Circ Physiol 302, H1285-93 (2012)
[61]B. A. MacVicar and E. A. Newman: Astrocyte regulation of blood flow in the brain. Cold Spring Harb Perspect Biol 7 (2015)
[62]M. H. Yousif, I. F. Benter and R. J. Roman: Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton Autacoid Pharmacol 29, 33-41 (2009)
[63]A. Anwar-mohamed, B. N. Zordoky, M. E. Aboutabl and A. O. El-Kadi: Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 61, 410-8 (2010)
[64]J. Antoun, S. Goulitquer, Y. Amet, Y. Dreano, J. P. Salaun, L. Corcos and E. Plee-Gautier: CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis. J Lipid Res 49, 2135-41 (2008)
[65]T. W. Wilson, M. Alonso-Galicia and R. J. Roman: Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31, 225-31 (1998)
[66]O. Ito, M. Alonso-Galicia, K. A. Hopp and R. J. Roman: Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol 274, F395-404 (1998)
[67]O. Ito and R. J. Roman: Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol 276, R1749-57 (1999)
[68]K. Omata, N. G. Abraham and M. L. Schwartzman: Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. Am J Physiol 262, F591-9 (1992)
[69]I. J. Tsai, K. D. Croft, I. B. Puddey, L. J. Beilin and A. Barden: 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am J Physiol Heart Circ Physiol 300, H1194-200 (2011)
[70]E. Hill, F. Fitzpatrick and R. C. Murphy: Biological activity and metabolism of 20-hydroxyeicosatetraenoic acid in the human platelet. Br J Pharmacol 106, 267-74 (1992)
[71]D. R. Harder, R. J. Roman, D. Gebremedhin, E. K. Birks and A. R. Lange: A common pathway for regulation of nutritive blood flow to the brain: arterial muscle membrane potential and cytochrome P450 metabolites. Acta Physiol Scand 164, 527-32 (1998)
[72]D. Zhu, M. Bousamra, 2nd, D. C. Zeldin, J. R. Falck, M. Townsley, D. R. Harder, R. J. Roman and E. R. Jacobs: Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 278, L335-43 (2000)
[73]D. C. Zeldin, J. D. Plitman, J. Kobayashi, R. F. Miller, J. R. Snapper, J. R. Falck, J. L. Szarek, R. M. Philpot and J. H. Capdevila: The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest 95, 2150-60 (1995)
[74]M. Rosolowsky and W. B. Campbell: Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 264, H327-35 (1993)
[75]M. Rosolowsky, J. R. Falck, J. T. Willerson and W. B. Campbell: Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res 66, 608-21 (1990)
[76]D. H. Munzenmaier and D. R. Harder: Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 278, H1163-7 (2000)
[77]N. J. Alkayed, J. Narayanan, D. Gebremedhin, M. Medhora, R. J. Roman and D. R. Harder: Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke 27, 971-9 (1996)
[78]S. C. Amruthesh, M. F. Boerschel, J. S. McKinney, K. A. Willoughby and E. F. Ellis: Metabolism of arachidonic acid to epoxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and prostaglandins in cultured rat hippocampal astrocytes. J Neurochem 61, 150-9 (1993)
[79]S. Wu, W. Chen, E. Murphy, S. Gabel, K. B. Tomer, J. Foley, C. Steenbergen, J. R. Falck, C. R. Moomaw and D. C. Zeldin: Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272, 12551-9 (1997)
[80]S. Wu, C. R. Moomaw, K. B. Tomer, J. R. Falck and D. C. Zeldin: Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271, 3460-8 (1996)
[81]Q. Y. Zhang, G. Raner, X. Ding, D. Dunbar, M. J. Coon and L. S. Kaminsky: Characterization of the cytochrome P450 CYP2J4: expression in rat small intestine and role in retinoic acid biotransformation from retinal. Arch Biochem Biophys 353, 257-64 (1998)
[82]D. C. Zeldin, J. Foley, J. E. Boyle, C. R. Moomaw, K. B. Tomer, C. Parker, C. Steenbergen and S. Wu: Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138, 1338-46 (1997)
[83]M. Schwartzman, N. R. Ferreri, M. A. Carroll, E. Songu-Mize and J. C. McGiff: Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature 314, 620-2 (1985)
[84]R. Quigley, M. Baum, K. M. Reddy, J. C. Griener and J. R. Falck: Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol 278, F949-53 (2000)
[85]O. Ito and R. J. Roman: Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension 33, 419-23 (1999)
[86]F. Park, W. E. Sweeney, G. Jia, T. Akbulut, B. Mueller, J. R. Falck, S. Birudaraju, R. J. Roman and E. D. Avner: Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD. Am J Physiol 296, F575-F582 (2009)
[87]F. Park, W. E. Sweeney, G. Jia, R. J. Roman and E. D. Avner: 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease. JASN 19, 1929-1939 (2008)
[88]J. Klawitter, J. Klawitter, K. McFann, A. T. Pennington, K. Z. Abebe, G. Brosnahan, M. A. Cadnapaphornchai, M. Chonchol, B. Gitomer, U. Christians and R. W. Schrier: Bioactive lipid mediators in polycystic kidney disease. J Lipid Res 55, 1139-1149 (2013)
[89]Y. H. Ma, M. L. Schwartzman and R. J. Roman: Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol 267, R579-89 (1994)
[90]H. Honeck, V. Gross, B. Erdmann, E. Kargel, R. Neunaber, A. F. Milia, W. Schneider, F. C. Luft and W. H. Schunck: Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension 36, 610-6 (2000)
[91]J. D. Imig, J. R. Falck, D. Gebremedhin, D. R. Harder and R. J. Roman: Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. Hypertension 22, 357-64 (1993)
[92]D. L. Kroetz, L. M. Huse, A. Thuresson and M. P. Grillo: Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol 52, 362-72 (1997)
[93]C. L. Laffer, M. Laniado-Schwartzman, M. H. Wang, A. Nasjletti and F. Elijovich: 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension. Hypertension 41, 703-8 (2003)
[94]I. Messer-Letienne, N. Bernard, R. J. Roman, J. Sassard and D. Benzoni: Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. Am J Hypertens 12, 398-404 (1999)
[95]I. Messer-Letienne, N. Bernard, R. J. Roman, J. Sassard and D. Benzoni: 20-Hydroxyeicosatetraenoic acid and renal function in Lyon hypertensive rats. Eur J Pharmacol 378, 291-7 (1999)
[96]D. Sacerdoti, N. G. Abraham, J. C. McGiff and M. L. Schwartzman: Renal cytochrome P-450-dependent metabolism of arachidonic acid in spontaneously hypertensive rats. Biochem Pharmacol 37, 521-7 (1988)
[97]K. Nakagawa, J. S. Marji, M. L. Schwartzman, M. R. Waterman and J. H. Capdevila: Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol Regul Integr Comp Physiol 284, R1055-62 (2003)
[98]B. Zhang, X. Yi, C. Wang, D. Liao, J. Lin and L. Chi: Cytochrome 4A11 Genetic Polymorphisms Increase Susceptibility to Ischemic Stroke and Associate with Atherothrombotic Events After Stroke in Chinese. Genet Test Mol Biomarkers 19, 235-41 (2015)
[99]H. Ding, G. Cui, L. Zhang, Y. Xu, X. Bao, Y. Tu, B. Wu, Q. Wang, R. Hui, W. Wang, R. T. Dackor, G. E. Kissling, D. C. Zeldin and D. W. Wang: Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics 20, 187-94 (2010)
[100]F. Elijovich and C. L. Laffer: The relationship between CYP4A11 and human hypertension. J Hypertens 26, 1712-4 (2008)
[101]Z. Fu, Y. Ma, X. Xie, D. Huang, H. Yang, T. Nakayama and N. Sato: A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 19, 60-5 (2013)
[102]Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, K. Matsumoto, Y. Ozawa and Y. Ma: Haplotype-based case study of human CYP4A11 gene and cerebral infarction in Japanese subject. Endocrine 33, 215-22 (2008)
[103]Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, Y. Ozawa and Y. Ma: A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men. J Hypertens 26, 453-61 (2008)
[104]Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, Y. Ozawa and Y. Ma: Haplotype-based case-control study of CYP4A11 gene and myocardial infarction. Hereditas 149, 91-8 (2012)
[105]Z. Fu, H. Yang, Y. Ma, D. Huang, X. Xie, Y. Zheng, Q. Zhu and T. Nakayama: Haplotype study of the CYP4A11 gene and coronary artery disease in Han and Uygur populations in China. Gene 512, 510-6 (2013)
[106]J. V. Gainer, M. S. Lipkowitz, C. Yu, M. R. Waterman, E. P. Dawson, J. H. Capdevila, N. J. Brown and A. S. Group: Association of a CYP4A11 variant and blood pressure in black men. J Am Soc Nephrol 19, 1606-12 (2008)
[107]C. L. Laffer, J. V. Gainer, M. R. Waterman, J. H. Capdevila, M. Laniado-Schwartzman, A. Nasjletti, N. J. Brown and F. Elijovich: The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 51, 767-72 (2008)
[108]J. Q. Liang, M. R. Yan, L. Yang, Q. Suyila, H. W. Cui and X. L. Su: Association of a CYP4A11 polymorphism and hypertension in the Mongolian and Han populations of China. Genet Mol Res 13, 508-17 (2014)
[109]K. Sugimoto, H. Akasaka, T. Katsuya, K. Node, T. Fujisawa, I. Shimaoka, O. Yasuda, M. Ohishi, T. Ogihara, K. Shimamoto and H. Rakugi: A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population. Hypertension 52, 1142-8 (2008)
[110]N. C. Ward, I. J. Tsai, A. Barden, F. M. van Bockxmeer, I. B. Puddey, J. M. Hodgson and K. D. Croft: Asingle nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 51, 1393-8 (2008)
[111]D. E. Stec, R. J. Roman, A. Flasch and M. J. Rieder: Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 30, 74-81 (2007)
[112]N. C. Ward, K. D. Croft, I. B. Puddey, M. Phillips, F. van Bockxmeer, L. J. Beilin and A. E. Barden: The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J Hypertens 32, 1495-502 (2014)
[113]S. Deng, G. Zhu, F. Liu, H. Zhang, X. Qin, L. Li and H. Zhiyi: CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 34, 664-8 (2010)
[114]C. Fava, M. Montagnana, P. Almgren, L. Rosberg, G. Lippi, B. Hedblad, G. Engstrom, G. Berglund, P. Minuz and O. Melander: The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52, 373-80 (2008)
[115]Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, K. Matsumoto, Y. Ozawa and Y. Ma: A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens 21, 1216-23 (2008)
[116]N. Miyata and R. J. Roman: Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 41, 175-93 (2005)
[117]C. C. Wu, T. Gupta, V. Garcia, Y. Ding and M. L. Schwartzman: 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 22, 1-12 (2014)
[118]S. L. Hoopes, V. Garcia, M. L. Edin, M. L. Schwartzman and D. C. Zeldin: Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat 120, 9-16 (2015)
[119]J. M. Williams, S. Murphy, M. Burke and R. J. Roman: 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 56, 336-44 (2010)
[120]A. H. Khan, J. R. Falck, V. L. Manthati, W. B. Campbell and J. D. Imig: Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Front Pharmacol 5, 216 (2014)
[121]J. D. Imig and M. A. Hye Khan: Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. Compr Physiol 6, 423-41 (2015)
[122]F. Kehl, L. Cambj-Sapunar, K. G. Maier, N. Miyata, S. Kametani, H. Okamoto, A. G. Hudetz, M. L. Schulte, D. Zagorac, D. R. Harder and R. J. Roman: 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol Heart Circ Physiol 282, H1556-65 (2002)
[123]T. Kawasaki, T. Marumo, K. Shirakami, T. Mori, H. Doi, M. Suzuki, Y. Watanabe, S. Chaki, A. Nakazato, Y. Ago, H. Hashimoto, T. Matsuda, A. Baba and H. Onoe: Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor. J Cereb Blood Flow Metab 32, 1737-46 (2012)
[124]L. Hacein-Bey, D. R. Harder, H. T. Meier, P. N. Varelas, N. Miyata, K. K. Lauer, J. F. Cusick and R. J. Roman: Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol 27, 1350-4 (2006)
[125]X. Y. Yi, D. X. Liao, C. Wang, W. Cheng, X. Q. Fu and B. Zhang: Cytochrome P450 Genetic Variants and Their Metabolite Levels Associated with Plaque Stability in Patients with Ischemic Stroke. J Atheroscler Thromb (2015)
[126]Y. Muroya, F. Fan, K. R. Regner, J. R. Falck, M. R. Garrett, L. A. Juncos and R. J. Roman: Deficiency in the Formation of 20-Hydroxyeicosatetraenoic Acid Enhances Renal Ischemia-Reperfusion Injury. J Am Soc Nephrol 26, 2460-9 (2015)
[127]K. R. Regner, A. Zuk, S. K. Van Why, B. D. Shames, R. P. Ryan, J. R. Falck, V. L. Manthati, M. E. McMullen, S. R. Ledbetter and R. J. Roman: Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int 75, 511-7 (2009)
[128]F. Catella, J. A. Lawson, D. J. Fitzgerald and G. A. FitzGerald: Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A 87, 5893-7 (1990)
[129]D. Sacerdoti, M. Balazy, P. Angeli, A. Gatta and J. C. McGiff: Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest 100, 1264-70 (1997)
[130]H. N. Althurwi, Z. H. Maayah, O. H. Elshenawy and A. O. El-Kadi: Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol. Drug Metab Dispos 43, 1254-66 (2015)
[131]Y. Han, H. Zhao, H. Tang, X. Li, J. Tan, Q. Zeng and C. Sun: 20-Hydroxyeicosatetraenoic acid mediates isolated heart ischemia/reperfusion injury by increasing NADPH oxidase-derived reactive oxygen species production. Circ J 77, 1807-16 (2013)
[132]B. Tunctan, B. Korkmaz, C. K. Buharalioglu, S. S. Firat, S. Anjaiah, J. Falck, R. J. Roman and K. U. Malik: A 20-hydroxyeicosatetraenoic acid agonist, N-(20-hydroxyeicosa-5(Z),14(Z)-dienoyl)glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock 30, 329-35 (2008)
[133]A. N. Sari, B. Korkmaz, M. S. Serin, M. Kacan, D. Unsal, C. K. Buharalioglu, S. Sahan Firat, V. L. Manthati, J. R. Falck, K. U. Malik and B. Tunctan: Effects of 5,14-HEDGE, a 20-HETE mimetic, on lipopolysaccharide-induced changes in MyD88/TAK1/IKKbeta/IkappaB-alpha/NF-kappaB pathway and circulating miR-150, miR-223, and miR-297 levels in a rat model of septic shock. Inflamm Res 63, 741-56 (2014)
[134]M. R. Metea and E. A. Newman: Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci 26, 2862-70 (2006)
[135]A. P. Zou, J. T. Fleming, J. R. Falck, E. R. Jacobs, D. Gebremedhin, D. R. Harder and R. J. Roman: 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. Am J Physiol 270, R228-37 (1996)
[136]D. Gebremedhin, A. R. Lange, J. Narayanan, M. R. Aebly, E. R. Jacobs and D. R. Harder: Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J Physiol 507, 771-81 (1998)
[137]N. Basora, G. Boulay, L. Bilodeau, E. Rousseau and M. D. Payet: 20-hydroxyeicosatetraenoic acid (20-HETE) activates mouse TRPC6 channels expressed in HEK293 cells. J Biol Chem 278, 31709-16 (2003)
[138]J. E. Brayden, S. Earley, M. T. Nelson and S. Reading: Transient receptor potential (TRP) channels, vascular tone and autoregulation of cerebral blood flow. Clin Exp Pharmacol Physiol 35, 1116-20 (2008)
[139]H. Wen, J. Ostman, K. J. Bubb, C. Panayiotou, J. V. Priestley, M. D. Baker and A. Ahluwalia: 20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 287, 13868-76 (2012)
[140]D. Gebremedhin, A. R. Lange, T. F. Lowry, M. R. Taheri, E. K. Birks, A. G. Hudetz, J. Narayanan, J. R. Falck, H. Okamoto, R. J. Roman, K. Nithipatikom, W. B. Campbell and D. R. Harder: Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 87, 60-5 (2000)
[141]Y. Ge, S. R. Murphy, Y. Lu, J. Falck, R. Liu and R. J. Roman: Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles. Prostaglandins Other Lipid Mediat 102-103, 42-8 (2013)
[142]Y. Ren, M. A. D’Ambrosio, J. L. Garvin, E. L. Peterson and O. A. Carretero: Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. Am J Physiol Renal Physiol 307, F533-8 (2014)
[143]A. P. Zou, J. D. Imig, M. Kaldunski, P. R. Ortiz de Montellano, Z. Sui and R. J. Roman: Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol 266, F275-82 (1994)
[144]Y. Ge, S. R. Murphy, F. Fan, J. M. Williams, J. R. Falck, R. Liu and R. J. Roman: Role of 20-HETE in the impaired myogenic and TGF responses of the Af-Art of Dahl salt-sensitive rats. Am J Physiol 307, F509-15 (2014)
[145]A. P. Zou, J. D. Imig, P. R. Ortiz de Montellano, Z. Sui, J. R. Falck and R. J. Roman: Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 266, F934-41 (1994)
[146]F. Fan, Y. Ge, S. Murphy, A. Geurts, H. Jacob and R. Roman: CYP4A1 transgenic rats generated using Sleeping Beauty transposon system restores the impaired myogenic responses in the afferent arteriole of Dahl S rats. (Abstract) Hypertens 62, A39 (2013)
[147]S. Murphy, F. Fan, R. Baker, A. Guerts, H. Jacob and R. J. Roman: Upregulation of Renal Medullary 20-HETE Production Opposes the Development of Hypertension in Sleeping Beauty Transposon CYP4A1 Transgenic Dahl S rats. FASEB J, (2012)
[148]Y. Chen, M. Medhora, J. R. Falck, K. A. Pritchard, Jr. and E. R. Jacobs: Mechanisms of activation of eNOS by 20-HETE and VEGF in bovine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 291, L378-85 (2006)
[149]D. Zhu, C. Zhang, M. Medhora and E. R. Jacobs: CYP4A mRNA, protein, and product in rat lungs: novel localization in vascular endothelium. J Appl Physiol, 93, 330-7 (2002)
[150]P. F. Pratt, J. R. Falck, K. M. Reddy, J. B. Kurian and W. B. Campbell: 20-HETE relaxes bovine coronary arteries through the release of prostacyclin. Hypertension 31, 237-41 (1998)
[151]M. Alonso-Galicia, J. R. Falck, K. M. Reddy and R. J. Roman: 20-HETE agonists and antagonists in the renal circulation. Am J Physiol 277, F790-F796 (1999)
[152]M. Yu, M. Alonso-Galicia, C. W. Sun, R. J. Roman, N. Ono, H. Hirano, T. Ishimoto, Y. K. Reddy, K. R. Katipally, K. M. Reddy, V. R. Gopal, J. Yu, M. Takhi and J. R. Falck: 20-hydroxyeicosatetraenoic acid (20-HETE): structural determinants for renal vasoconstriction. Bioorg Med Chem 11, 2803-21 (2003)
[153]P. R. Ortiz de Montellano and N. O. Reich: Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J Biol Chem 259, 4136-41 (1984)
[154]A.-P. Zou, Y.-H. Ma, Z.-H. Sui, P. O. De Montellano, J. E. Clark, B. S. Masters and R. J. Roman: Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J JPharmacol Exp Ther 268, 474-481 (1994)
[155]M. Alonso-Galicia, H. A. Drummond, K. K. Reddy, J. R. Falck and R. J. Roman: Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29, 320-5 (1997)
[156]M. H. Wang, E. Brand-Schieber, B. A. Zand, X. Nguyen, J. R. Falck, N. Balu and M. L. Schwartzman: Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284, 966-73 (1998)
[157]N. Miyata, K. Taniguchi, T. Seki, T. Ishimoto, M. Sato-Watanabe, Y. Yasuda, M. Doi, S. Kametani, Y. Tomishima, T. Ueki, M. Sato and K. Kameo: HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133, 325-9 (2001)
[158]T. Omura, Y. Tanaka, N. Miyata, C. Koizumi, T. Sakurai, M. Fukasawa, K. Hachiuma, T. Minagawa, T. Susumu, S. Yoshida, S. Nakaike, S. Okuyama, D. R. Harder and R. J. Roman: Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 37, 1307-13 (2006)
[159]M. Sato, T. Ishii, Y. Kobayashi-Matsunaga, H. Amada, K. Taniguchi, N. Miyata and K. Kameo: Discovery of a N’-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett 11, 2993-5 (2001)
[160]K. M. Hoagland, A. K. Flasch and R. J. Roman: Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42, 669-673 (2003)
[161]J. M. Williams, A. Sarkis, B. Lopez, R. P. Ryan, A. K. Flasch and R. J. Roman: Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension 49, 687-94 (2007)
[162]V. G. Pandey, V. Garcia, G. Joseph, F. F. Zhang, B. Shkolnik, P. Mishra, J. R. Falck, J. Capdevila and M. L. Schwartzman: 20-SOLA, a novel water-soluble 20-HETE antagonist, elicits natriuresis and abrogates hypertension in CYP4A14 knockout mice. Hypertension 64, A047 (2014)
[163]V. Garcia, B. Shkolnik, V. Pandey, J. Capdevila, J. Falck and M. Schwartzman: 20-SOLA, a Novel Water Soluble 20-HETE Antagonist, Reduces Blood Pressure Through Regulation of Vascular ACE Expression via an IKK Dependent Pathway. FASEB J 29, 647.9. (2015)
[164]J. Deanfield, A. Donald, C. Ferri, C. Giannattasio, J. Halcox, S. Halligan, A. Lerman, G. Mancia, J. J. Oliver, A. C. Pessina, D. Rizzoni, G. P. Rossi, A. Salvetti, E. L. Schiffrin, S. Taddei, D. J. Webb, E. Working Group on and H. Endothelial Factors of the European Society of: Endothelial function and dysfunction. PartI: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23, 7-17 (2005)
[165]J. Cheng, J. S. Ou, H. Singh, J. R. Falck, D. Narsimhaswamy, K. A. Pritchard, Jr. and M. L. Schwartzman: 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol 294, H1018-26 (2008)
[166]J. Cheng, C. C. Wu, K. H. Gotlinger, F. Zhang, J. R. Falck, D. Narsimhaswamy and M. L. Schwartzman: 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 332, 57-65 (2010)
[167]P. Toth, A. Csiszar, D. Sosnowska, Z. Tucsek, P. Cseplo, Z. Springo, S. Tarantini, W. E. Sonntag, Z. Ungvari and A. Koller: Treatment with the cytochrome P450 omega-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats. Br J Pharmacol 168, 1878-88 (2013)
[168]K. M. Dunn, M. Renic, A. K. Flasch, D. R. Harder, J. Falck and R. J. Roman: Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol, 295, H2455-65 (2008)
[169]M. L. Schwartzman, J. L. da Silva, F. Lin, M. Nishimura and N. G. Abraham: Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron 73, 652-63 (1996)
[170]A. Blanton, R. Nsaif, H. Hercule and A. Oyekan: Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypertens 24, 1865-72 (2006)
[171]P. Fidelis, L. Wilson, K. Thomas, M. Villalobos and A. O. Oyekan: Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med, 235, 1365-74 (2010)
[172]C. C. Wu, S. Mei, J. Cheng, Y. Ding, A. Weidenhammer, V. Garcia, F. Zhang, K. Gotlinger, V. L. Manthati, J. R. Falck, J. H. Capdevila and M. L. Schwartzman: Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol 24, 1288-96 (2013)
[173]T. Ishizuka, J. Cheng, H. Singh, M. D. Vitto, V. L. Manthati, J. R. Falck and M. Laniado-Schwartzman: 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 324, 103-10 (2008)
[174]R. N. Schuck, K. N. Theken, M. L. Edin, M. Caughey, A. Bass, K. Ellis, B. Tran, S. Steele, B. P. Simmons, F. B. Lih, K. B. Tomer, M. C. Wu, A. L. Hinderliter, G. A. Stouffer, D. C. Zeldin and C. R. Lee: Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis 227, 442-8 (2013)
[175]N. C. Ward, I. B. Puddey, J. M. Hodgson, L. J. Beilin and K. D. Croft: Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med 38, 1032-6 (2005)
[176]N. C. Ward, J. Rivera, J. Hodgson, I. B. Puddey, L. J. Beilin, J. R. Falck and K. D. Croft: Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110, 438-43 (2004)
[177]J. Wang, H. Li, J. He, B. Li, Q. Bao, X. Zhang, Z. Lv, Y. Zhang, J. Han, D. Ai and Y. Zhu: 20-Hydroxyeicosatetraenoic acid involved in endothelial activation and thrombosis. Am J Physiol Heart Circ Physiol 308, H1359-67 (2015)
[178]N. F. Renna: Oxidative stress, vascular remodeling, and vascular inflammation in hypertension. Int J Hypertens 710136 (2013).
[179]N. F. Renna, N. de Las Heras and R. M. Miatello: Pathophysiology of vascular remodeling in hypertension. Int J Hypertens 808353 (2013)
[180]J. C. McGrath, C. Deighan, A. M. Briones, M. M. Shafaroudi, M. McBride, J. Adler, S. M. Arribas, E. Vila and C. J. Daly: New aspects of vascular remodelling: the involvement of all vascular cell types. Exp Physiol 90, 469-75 (2005)
[181]B. L. Langille: Remodeling of developing and mature arteries: endothelium, smooth muscle, and matrix. J Cardiovasc Pharmacol 21, S11-7 (1993)
[182]J. H. Parmentier, M. M. Muthalif, A. T. Nishimoto and K. U. Malik: 20-Hydroxyeicosatetraenoic acid mediates angiotensin ii-induced phospholipase d activation in vascular smooth muscle cells. Hypertension 37, 623-9 (2001)
[183]D. E. Stec, K. P. Gannon, J. S. Beaird and H. A. Drummond: 20-Hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem 19, 121-8 (2007)
[184]A. M. Guo, B. Janic, J. Sheng, J. R. Falck, R. J. Roman, P. A. Edwards, A. S. Arbab and A. G. Scicli: The cytochrome P4504A/F-20-hydroxyeicosatetraenoic acid system: a regulator of endothelial precursor cells derived from human umbilical cord blood. J Pharmacol Exp Ther 338, 421-9 (2011)
[185]A. M. Guo, G. Scicli, J. Sheng, J. C. Falck, P. A. Edwards and A. G. Scicli: 20-HETE can act as a nonhypoxic regulator of HIF-1alpha in human microvascular endothelial cells. Am J Physiol Heart Circ Physiol 297, H602-13 (2009)
[186]J. Cheng, M. L. Edin, S. L. Hoopes, H. Li, J. A. Bradbury, J. P. Graves, L. M. DeGraff, F. B. Lih, V. Garcia, J. S. Shaik, K. B. Tomer, G. P. Flake, J. R. Falck, C. R. Lee, S. M. Poloyac, M. L. Schwartzman and D. C. Zeldin: Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB J 28, 2915-31 (2014)
[187]L. Chen, R. Ackerman, M. Saleh, K. H. Gotlinger, M. Kessler, L. G. Mendelowitz, J. R. Falck, A. S. Arbab, A. G. Scicli, M. L. Schwartzman, J. Yang and A. M. Guo: 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther 348, 442-51 (2014)
[188]S. Lu, C. Zhu, A. Long, L. Tan, Q. Li and Y. Zhu: Effect of 20-hydroxyeicosatetraenoic acid on biological behavior of human villous trophoblasts and uterine vascular smooth muscle cells. Mol Med Rep 9, 1889-94 (2014)
[189]Z. Wang, X. Tang, Y. Li, C. Leu, L. Guo, X. Zheng and D. Zhu: 20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. Eur J Pharmacol 588, 9-17 (2008)
[190]G. L. Baumbach and D. D. Heistad: Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13, 968-72 (1989)
[191]R. D. Levere, P. Martasek, B. Escalante, M. L. Schwartzman and N. G. Abraham: Effect of heme arginate administration on bloodhttp://dx.doi.org/10.1172/JCI114686 pressure in spontaneously hypertensive rats. J Clin Invest 86, 213-9 (1990)
[192]M. L. Schwartzman, K. Omata, F. M. Lin, R. K. Bhatt, J. R. Falck and N. G. Abraham: Detection of 20-hydroxyeicosatetraenoic acid in rat urine. Biochem Biophys Res Commun 180, 445-9 (1991)
[193]D. Gebremedhin, Y. H. Ma, J. D. Imig, D. R. Harder and R. J. Roman: Role of cytochrome P-450 in elevating renal vascular tone in spontaneously hypertensive rats. J Vasc Res 30, 53-60 (1993)
[194]J. C. Frisbee, R. J. Roman, J. R. Falck, J. R. Linderman and J. H. Lombard: Impairment of flow-induced dilation of skeletal muscle arterioles with elevated oxygen in normotensive and hypertensive rats. Microvasc Res 60, 37-48 (2000)
[195]Y. Ding, C. C. Wu, V. Garcia, I. Dimitrova, A. Weidenhammer, G. Joseph, F. Zhang, V. L. Manthati, J. R. Falck, J. H. Capdevila and M. L. Schwartzman: 20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension. Am J Physiol Renal Physiol 305, F753-63 (2013)
[196]V. Garcia, G. Joseph, B. Shkolnik, Y. Ding, F. F. Zhang, K. Gotlinger, J. R. Falck, R. Dakarapu, J. H. Capdevila, K. E. Bernstein and M. L. Schwartzman: Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 309, R71-8 (2015)
[197]F. Ljuca and G. Drevensek: Endothelin-1 induced vascular smooth muscle cell proliferation is mediated by cytochrome p-450 arachidonic acid metabolites. Bosn J Basic Med Sci 10, 223-6 (2010)
[198]L. Chen, R. Ackerman and A. M. Guo: 20-HETE in neovascularization. Prostaglandins Other Lipid Mediat 98, 63-8 (2012) do
[199]M. B. Sewer, D. R. Koop and E. T. Morgan: Endotoxemia in rats is associated with induction of the P450 4A subfamily and suppression of several other forms of cytochrome P450. Drug Metab Dispos 24, 401-7 (1996)
[200]F. A. Yaghini, C. Zhang, J. H. Parmentier, A. M. Estes, N. Jafari, S. A. Schaefer and K. U. Malik: Contribution of arachidonic acid metabolites derived via cytochrome P450 4A to angiotensin II-induced neointimal growth. Hypertension 45, 1182-7 (2005)
[201]G. Sa, G. Murugesan, M. Jaye, Y. Ivashchenko and P. L. Fox: Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem 270, 2360-6 (1995)
[202]S. L. Amaral, K. G. Maier, D. N. Schippers, R. J. Roman and A. S. Greene: CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 284, H1528-35 (2003)
[203]M. Jiang, A. Mezentsev, R. Kemp, K. Byun, J. R. Falck, J. M. Miano, A. Nasjletti, N. G. Abraham and M. Laniado-Schwartzman: Smooth muscle--specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res 94, 167-74 (2004)
[204]P. Chen, M. Guo, D. Wygle, P. A. Edwards, J. R. Falck, R. J. Roman and A. G. Scicli: Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166, 615-24 (2005)
[205]A. Dhanasekaran, S. Bodiga, S. Gruenloh, Y. Gao, L. Dunn, J. R. Falck, J. N. Buonaccorsi, M. Medhora and E. R. Jacobs: 20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells. Am J Physiol Heart Circ Physiol 296, H777-86 (2009)
[206]T. F. Borin, D. A. Zuccari, B. V. Jardim-Perassi, L. C. Ferreira, A. S. Iskander, N. R. Varma, A. Shankar, A. M. Guo, G. Scicli and A. S. Arbab: HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice. PLoS One 9, e116247 (2014)
[207]W. Yu, L. Chen, Y. Q. Yang, J. R. Falck, A. M. Guo, Y. Li and J. Yang: Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol 68, 619-29 (2011)
[208]M. Guo, R. J. Roman, J. D. Fenstermacher, S. L. Brown, J. R. Falck, A. S. Arbab, P. A. Edwards and A. G. Scicli: 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N’-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317, 97-108 (2006)
[209]M. Guo, R. J. Roman, J. R. Falck, P. A. Edwards and A. G. Scicli: Human U251 glioma cell proliferation is suppressed by HET0016 (N-hydroxy-N’-(4-butyl-2-methylphenyl)formamidine), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315, 526-33 (2005)
[210]A. M. Guo, J. Sheng, G. M. Scicli, A. S. Arbab, N. L. Lehman, P. A. Edwards, J. R. Falck, R. J. Roman and A. G. Scicli: Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. J Pharmacol Exp Ther 327, 10-9 (2008)
[211]A. Alexanian, B. Miller, R. J. Roman and A. Sorokin: 20-HETE-producing enzymes are up-regulated in human cancers. Cancer Genomics Proteomics 9, 163-9 (2012)
[212]N. Mozzillo, E. Pennacchioli, S. Gandini, C. Caraco, A. Crispo, G. Botti, S. Lastoria, M. Barberis, F. Verrecchia and A. Testori: Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol 20, 2780-6 (2013)
[213]A. Alexanian and A. Sorokin: Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potential. Onco Targets Ther 6, 243-55 (2013)
[214]A. L. Johnson, K. Z. Edson, R. A. Totah and A. E. Rettie: Cytochrome P450 omega-Hydroxylases in Inflammation and Cancer. Adv Pharmacol 74, 223-62 (2015)
[215]X. Y. Yu, C. S. Glantz, J. Yao, H. He, A. J. Petrocchi, D. K. Craig, J. T. Ciolek and A. E. Booth: Enhancing the chemical mixture methodology in emergency preparedness and consequence assessment analysis. Toxicology 313, 174-84 (2013)
[216]D. Panigrahy, A. Kaipainen, E. R. Greene and S. Huang: Cytochrome P450-derived eicosanoids: the neglected pathway in can
[217]Y. Zhang, M. N. Hoda, X. Zheng, W. Li, P. Luo, K. R. Maddipati, T. Seki, A. Ergul and M. H. Wang: Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition. Am J Physiol Regul Integr Comp Physiol 307, R693-703 (2014)
[218]M. M. Bednar, C. E. Gross, M. K. Balazy, Y. Belosludtsev, D. T. Colella, J. R. Falck and M. Balazy: 16(R)-hydroxy-5,8,11,14-eicosatetraenoic acid, a new arachidonate metabolite in human polymorphonuclear leukocytes. Biochem Pharmacol 60, 447-55 (2000)
[219]M. Rosolowsky, J. R. Falck and W. B. Campbell: Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Biochim Biophys Acta 1300, 143-50 (1996)
[220]Y. Zhu, E. B. Schieber, J. C. McGiff and M. Balazy: Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25, 854-9 (1995)
[221]J. Y. Liu, N. Li, J. Yang, N. Li, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu and B. D. Hammock: Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A 107, 17017-22 (2010)
[222]C. L. Bos, D. J. Richel, T. Ritsema, M. P. Peppelenbosch and H. H. Versteeg: Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36, 1187-205 (2004)
[223]O. Kowal-Bielecka, K. Kowal, O. Distler, J. Rojewska, A. Bodzenta-Lukaszyk, B. A. Michel, R. E. Gay, S. Gay and S. Sierakowski: Cyclooxygenase-and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 52, 3783-91 (2005)
[224]N. Sehgal, V. Agarwal, R. K. Valli, S. D. Joshi, L. Antonovic, H. W. Strobel and V. Ravindranath: Cytochrome P450 4f, a potential therapeutic target limiting neuroinflammation. Biochem Pharmacol 82, 53-64 (2011)
[225]Y. Wang, J. Zhao, A. Kalsotra, C. M. Turman, R. J. Grill, P. K. Dash and H. W. Strobel: CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury. J Neurotrauma 25, 1187-94 (2008)
[226]X. Liu, P. Zhu and B. D. Freedman: Multiple eicosanoid-activated nonselective cation channels regulate B-lymphocyte adhesion to integrin ligands. Am J Physiol Cell Physiol 290, C873-82 (2006)
[227]B. Tunctan, B. Korkmaz, A. N. Sari, M. Kacan, D. Unsal, M. S. Serin, C. K. Buharalioglu, S. Sahan-Firat, T. Cuez, W. H. Schunck, V. L. Manthati, J. R. Falck and K. U. Malik: Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock. Nitric Oxide 33, 18-41 (2013)
[228]B. Tunctan, B. Korkmaz, A. N. Sari, M. Kacan, D. Unsal, M. S. Serin, C. K. Buharalioglu, S. Sahan-Firat, T. Cuez, W. H. Schunck, J. R. Falck and K. U. Malik: 5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKKbeta/IkappaB-alpha/NF-kappaB pathway, and proinflammatory cytokine formation. Prostaglandins Other Lipid Mediat 102-103, 31-41 (2013)
[229]C. W. Sun, M. Alonso-Galicia, M. R. Taheri, J. R. Falck, D. R. Harder and R. J. Roman: Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ Res 83, 1069-79 (1998)
[230]M. Alonso-Galicia, A. G. Hudetz, H. Shen, D. R. Harder and R. J. Roman: Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke 30, 2727-34; discussion 2734 (1999)
[231]M. H. Wang, J. Wang, H. H. Chang, B. A. Zand, M. Jiang, A. Nasjletti and M. Laniado-Schwartzman: Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. Am J Physiol Renal Physiol 285, F295-302 (2003)
[232]U. Hoff, I. Lukitsch, L. Chaykovska, M. Ladwig, C. Arnold, V. L. Manthati, T. F. Fuller, W. Schneider, M. Gollasch, D. N. Muller, B. Flemming, E. Seeliger, F. C. Luft, J. R. Falck, D. Dragun and W. H. Schunck: Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int 79, 57-65 (2011)
[233]D. L. Lee, J. L. Wilson, R. Duan, T. Hudson and A. El-Marakby: Peroxisome Proliferator-Activated Receptor-alpha Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension. PPAR Res 502631 (2011)
[234]P. Zhu, X. Liu, E. F. Labelle and B. D. Freedman: Mechanisms of hypotonicity-induced calcium signaling and integrin activation by arachidonic acid-derived inflammatory mediators in B cells. J Immunol 175, 4981-9 (2005)
[235]J. P. Broderick, T. G. Brott, J. E. Duldner, T. Tomsick and A. Leach: Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 25, 1342-7 (1994)
[236]J. W. Hop, G. J. Rinkel, A. Algra and J. van Gijn: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 28, 660-4 (1997)
[237]H. P. Adams, Jr., N. F. Kassell, J. C. Torner, D. W. Nibbelink and A. L. Sahs: Early management of aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 54, 141-5 (1981)
[238]H. L. Tian, Z. Geng, Y. H. Cui, J. Hu, T. Xu, H. L. Cao, S. W. Chen and H. Chen: Risk factors for posttraumatic cerebral infarction in patients with moderate or severe head trauma. Neurosurg Rev 31, 431-6; discussion 436-7 (2008)
[239]I. Tawil, D. M. Stein, S. E. Mirvis and T. M. Scalea: Posttraumatic cerebral infarction: incidence, outcome, and risk factors. J Trauma 64, 849-53 (2008)
[240]M. D. Vergouwen, D. Ilodigwe and R. L. Macdonald: Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 42, 924-9 (2011)
[241]B. Weir, M. Grace, J. Hansen and C. Rothberg: Time course of vasospasm in man. J Neurosurg 48, 173-8 (1978)
[242]J. F. Megyesi, B. Vollrath, D. A. Cook and J. M. Findlay: In vivo animal models of cerebral vasospasm: a review. Neurosurgery 46, 448-60 (2000)
[243]C. G. Sobey and F. M. Faraci: Subarachnoid haemorrhage: what happens to the cerebral arteries? Clin Exp Pharmacol Physiol 25, 867-76 (1998)
[244]J. B. Bederson, A. L. Levy, W. H. Ding, R. Kahn, C. A. DiPerna, A. L. Jenkins, 3rd and P. Vallabhajosyula: Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 42, 352-60 (1998)
[245]R. L. Macdonald and B. K. Weir: A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 22, 971-82 (1991)
[246]R. M. Pluta, J. K. Afshar, R. J. Boock and E. H. Oldfield: Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. J Neurosurg 88, 557-61 (1998)
[247]R. L. Macdonald, B. K. Weir, L. S. Marton, Z. D. Zhang, M. Sajdak, L. M. Johns, A. Kowalczuk and M. Borsody: Role of adenosine 5’-triphosphate in vasospasm after subarachnoid hemorrhage: human investigations. Neurosurgery 48, 854-62; (2001)
[248]W. M. Armstead: Endothelins and the role of endothelin antagonists in the management of posttraumatic vasospasm. Curr Pharm Des 10, 2185-92 (2004)
[249]S. Juvela: Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 92, 390-400 (2000)
[250]S. W. Hoffman, B. A. Rzigalinski, K. A. Willoughby and E. F. Ellis: Astrocytes generate isoprostanes in response to trauma or oxygen radicals. J Neurotrauma 17, 415-20 (2000)
[251]S. W. Hoffman, S. Moore and E. F. Ellis: Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 28, 844-9 (1997)
[252]L. Cambj-Sapunar, M. Yu, D. R. Harder and R. J. Roman: Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke 34, 1269-75 (2003)
[253]D. R. Harder: Increased sensitivity of cat cerebral arteries to serotonin upon elevation of transmural pressure. Pflugers Arch 411, 698-700 (1988)
[254]A. D. Mendelow, T. A. McCalden, J. Hattingh, A. Coull, C. Rosendorff and B. H. Eidelman: Cerebrovascular reactivity and metabolism after subarachnoid hemorrhage in baboons. Stroke 12, 58-65 (1981)
[255]M. Clozel and H. Watanabe: BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 52, 825-34 (1993)
[256]P. L. Foley, H. H. Caner, N. F. Kassell and K. S. Lee: Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 34, 108-12 (1994)
[257]J. Josko, S. Hendryk, H. Jedrzejowska-Szypula, B. Gwozdz, Z. S. Herman and R. Gawlik: Influence endothelin ETA receptor antagonist--BQ-123--on changes of endothelin-1 level in plasma of rats with acute vasospasm following subarachnoid hemorrhage. J Physiol Pharmacol 49, 367-75 (1998)
[258]M. Kaminogo, M. Yonekura, M. Onizuka, A. Yasunaga and S. Shibata: Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. Neurol Med Chir 38, 704-8 (1998)
[259]H. Takeuchi, M. Tanabe, H. Okamoto and M. Yamazaki: Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm. Neurol Res 21, 513-6 (1999)
[260]M. Yamaguchi, C. Zhou, A. Nanda and J. H. Zhang: Ras protein contributes to cerebral vasospasm in a canine double-hemorrhage model. Stroke 35, 1750-5 (2004)
[261]G. Wickman, C. Lan and B. Vollrath: Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm. Circ Res 92, 809-16 (2003)
[262]K. Obara, S. Nishizawa, M. Koide, K. Nozawa, A. Mitate, T. Ishikawa and K. Nakayama: Interactive role of protein kinase C-delta with rho-kinase in the development of cerebral vasospasm in a canine two-hemorrhage model. J Vasc Res 42, 67-76 (2005)
[263]Y. Miyagi, R. C. Carpenter, T. Meguro, A. D. Parent and J. H. Zhang: Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 93, 471-6 (2000)
[264]T. Sasaki, H. Kasuya, H. Onda, A. Sasahara, S. Goto, T. Hori and I. Inoue: Role of p38 mitogen-activated protein kinase on cerebral vasospasm after subarachnoid hemorrhage. Stroke 35, 1466-70 (2004)
[265]I. Laher and J. H. Zhang: Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab 21, 887-906 (2001)
[266]T. Matsui, M. Sugawa, H. Johshita, Y. Takuwa and T. Asano: Activation of the protein kinase C-mediated contractile system in canine basilar artery undergoing chronic vasospasm. Stroke 22, 1183-7 (1991)
[267]G. Kusaka, H. Kimura, I. Kusaka, E. Perkins, A. Nanda and J. H. Zhang: Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 99, 383-90 (2003)
[268]S. Nishizawa, S. Yamamoto and K. Uemura: Interrelation between protein kinase C and nitric oxide in the development of vasospasm after subarachnoid hemorrhage. Neurol Res 18, 89-95 (1996)
[269]D. R. Harder, P. Dernbach and A. Waters: Possible cellular mechanism for cerebral vasospasm after experimental subarachnoid hemorrhage in the dog. J Clin Invest 80, 875-80 (1987)
[270]M. A. Murray, F. M. Faraci and D. D. Heistad: Effect of protein kinase C inhibitors on endothelin-and vasopressin-induced constriction of the rat basilar artery. Am J Physiol 263H1643-9 (1992)
[271]P. Kim, V. B. Schini, T. M. Sundt, Jr. and P. M. Vanhoutte: Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage. Circ Res 70, 248-56 (1992)
[272]C. G. Sobey, D. D. Heistad and F. M. Faraci: Effect of subarachnoid hemorrhage on dilatation of rat basilar artery in vivo. Am J Physiol 271, H126-32 (1996)
[273]S. Yamamoto, S. Nishizawa, T. Yokoyama, H. Ryu and K. Uemura: Subarachnoid hemorrhage impairs cerebral blood flow response to nitric oxide but not to cyclic GMP in large cerebral arteries. Brain Res 757, 1-9 (1997)
[274]A. Y. Schwartz, F. A. Sehba and J. B. Bederson: Decreased nitric oxide availability contributes to acute cerebral ischemia after subarachnoid hemorrhage. Neurosurgery 47, 208-14 (2000)
[275]S. M. Poloyac, R. B. Reynolds, H. Yonas and M. E. Kerr: Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J Neurosci Methods 144, 257-63 (2005)
[276]M. K. Donnelly, E. A. Crago, Y. P. Conley, J. R. Balzer, D. Ren, A. F. Ducruet, P. M. Kochanek, P. R. Sherwood and S. M. Poloyac: 20-HETE is associated with unfavorable outcomes in subarachnoid hemorrhage patients. J Cereb Blood Flow Metab 35, 1515-22 (2015)
[277]D. A. Siler, R. P. Martini, J. P. Ward, J. W. Nelson, R. N. Borkar, K. L. Zuloaga, J. J. Liu, S. L. Fairbanks, J. S. Raskin, V. C. Anderson, A. Dogan, R. K. Wang, N. J. Alkayed and J. S. Cetas: Protective role of p450 epoxyeicosanoids in subarachnoid hemorrhage. Neurocrit Care 22, 306-19 (2015)
[278]J. G. Pilitsis, W. M. Coplin, M. H. O’Regan, J. M. Wellwood, F. G. Diaz, M. R. Fairfax, D. B. Michael and J. W. Phillis: Measurement of free fatty acids in cerebrospinal fluid from patients with hemorrhagic and ischemic stroke. Brain Res 985, 198-201 (2003)
[279]K. Takeuchi, M. Renic, Q. C. Bohman, D. R. Harder, N. Miyata and R. J. Roman: Reversal of delayed vasospasm by an inhibitor of the synthesis of 20-HETE. Am J Physiol Heart Circ Physiol 289, H2203-11 (2005)
[280]N. Miyata, T. Seki, Y. Tanaka, T. Omura, K. Taniguchi, M. Doi, K. Bandou, S. Kametani, M. Sato, S. Okuyama, L. Cambj-Sapunar, D. R. Harder and R. J. Roman: Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 (N-(3-chloro-4-morpholin-4-yl) phenyl-N’-hydroxyimido formamide), on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther 314, 77-85 (2005)
[281]J. P. Dreier, S. Major, A. Manning, J. Woitzik, C. Drenckhahn, J. Steinbrink, C. Tolias, A. I. Oliveira-Ferreira, M. Fabricius, J. A. Hartings, P. Vajkoczy, M. Lauritzen, U. Dirnagl, G. Bohner, A. J. Strong and C. s. group: Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 132, 1866-81 (2009)
[282]J. C. Fordsmann, R. W. Ko, H. B. Choi, K. Thomsen, B. M. Witgen, C. Mathiesen, M. Lonstrup, H. Piilgaard, B. A. MacVicar and M. Lauritzen: Increased 20-HETE synthesis explains reduced cerebral blood flow but not impaired neurovascular coupling after cortical spreading depression in rat cerebral cortex. J Neurosci 33, 2562-70 (2013)
[283]J. S. Shaik, S. M. Poloyac, P. M. Kochanek, H. Alexander, D. L. Tudorascu, R. S. Clark and M. D. Manole: 20-Hydroxyeicosatetraenoic Acid Inhibition by HET0016 Offers Neuroprotection, Decreases Edema, and Increases Cortical Cerebral Blood Flow in a Pediatric Asphyxial Cardiac Arrest Model in Rats. J Cereb Blood Flow Metab 35, 1757-63 (2015)
[284]G. E. Cold: Cerebral blood flow in the acute phase after head injury. Part 2: Correlation to intraventricular pressure (IVP), cerebral perfusion pressure (CPP), PaCO2, ventricular fluid lactate, lactate/pyruvate ratio and pH. Acta Anaesthesiol Scand 25, 332-5 (1981)
[285]G. E. Cold and F. T. Jensen: Cerebral autoregulation in unconscious patients with brain injury. Acta Anaesthesiol Scand 22, 270-80 (1978)
[286]J. Overgaard and W. A. Tweed: Cerebral circulation after head injury. 1. Cerebral blood flow and its regulation after closed head injury with emphasis on clinical correlations. J Neurosurg 41, 531-41 (1974)
[287]O. B. Paulson, S. Strandgaard and L. Edvinsson: Cerebral autoregulation. Cerebrovasc Brain Metab Rev 2, 161-92 (1990)
[288]A. J. Strong, M. Fabricius, M. G. Boutelle, S. J. Hibbins, S. E. Hopwood, R. Jones, M. C. Parkin and M. Lauritzen: Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33, 2738-43 (2002)
[289]M. Hiler, M. Czosnyka, P. Hutchinson, M. Balestreri, P. Smielewski, B. Matta and J. D. Pickard: Predictive value of initial computerized tomography scan, intracranial pressure, and state of autoregulation in patients with traumatic brain injury. J Neurosurg 104, 731-7 (2006)
[290]E. A. Schmidt, M. Czosnyka, L. A. Steiner, M. Balestreri, P. Smielewski, S. K. Piechnik, B. F. Matta and J. D. Pickard: Asymmetry of pressure autoregulation after traumatic brain injury. J Neurosurg 99, 991-8 (2003)
[291]L. A. Steiner, M. Czosnyka, S. K. Piechnik, P. Smielewski, D. Chatfield, D. K. Menon and J. D. Pickard: Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med 30, 733-8 (2002)
[292]K. M. Brady, D. H. Shaffner, J. K. Lee, R. B. Easley, P. Smielewski, M. Czosnyka, G. I. Jallo and A. M. Guerguerian: Continuous monitoring of cerebrovascular pressure reactivity after traumatic brain injury in children. Pediatrics 124, e1205-12 (2009)
[293]E. P. Wei, R. G. Lamb and H. A. Kontos: Increased phospholipase C activity after experimental brain injury. J Neurosurg 56, 695-8 (1982)
[294]P. Homayoun, E. B. Rodriguez de Turco, N. E. Parkins, D. C. Lane, J. Soblosky, M. E. Carey and N. G. Bazan: Delayed phospholipid degradation in rat brain after traumatic brain injury. J Neurochem 69, 199-205 (1997)
[295]J. W. Phillis and M. H. O’Regan: A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Brain Res Rev 44, 13-47 (2004)
[296]J. G. Pilitsis, W. M. Coplin, M. H. O’Regan, J. M. Wellwood, F. G. Diaz, M. R. Fairfax, D. B. Michael and J. W. Phillis: Free fatty acids in cerebrospinal fluids from patients with traumatic brain injury. Neurosci Lett 349, 136-8 (2003)
[297]M. Birnie, R. Morrison, R. Camara and K. I. Strauss: Temporal changes of cytochrome P450 (Cyp) and eicosanoid-related gene expression in the rat brain after traumatic brain injury. BMC Genomics 14, 303 (2013)
[298]G. Stoll, C. Kleinschnitz and B. Nieswandt: Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112, 3555-62 (2008)
[299]M. D. Ginsberg: Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 34, 214-23 (2003)
[300]S. T. Carmichael: Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2, 396-409 (2005)
[301]K. A. Hossmann: Experimental models for the investigation of brain ischemia. Cardiovasc Res 39, 106-20 (1998)
[302]J. Folbergrova, H. Memezawa, M. L. Smith and B. K. Siesjo: Focal and perifocal changes in tissue energy state during middle cerebral artery occlusion in normo-and hyperglycemic rats. J Cereb Blood Flow Metab 12, 25-33 (1992)
[303]E. Sarvary, J. H. Halsey, K. A. Conger, J. H. Garcia and A. G. Kovach: ATP and pH predictors of histologic damage following global cerebral ischemia in the rat. Acta Physiol Hung 82, 109-24 (1994)
[304]M. Chen, D. J. Won, S. Krajewski and R. A. Gottlieb: Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 277, 29181-6 (2002)
[305]K. B. MacKay, T. R. Patel, S. L. Galbraith, G. N. Woodruff and J. McCulloch: The relationship between glutamate release and cerebral blood flow after focal cerebral ischaemia in the cat: effect of pretreatment with enadoline (a kappa receptor agonist). Brain Res 712, 329-34 (1996)
[306]E. E. Tseng, M. V. Brock, C. C. Kwon, M. Annanata, M. S. Lange, J. C. Troncoso, M. V. Johnston and W. A. Baumgartner: Increased intracerebral excitatory amino acids and nitric oxide after hypothermic circulatory arrest. Ann Thorac Surg 67, 371-6 (1999)
[307]L. L. Werling, H. M. Jacocks, 3rd, R. E. Rosenthal and G. Fiskum: Dopamine release from canine striatum following global cerebral ischemia/reperfusion. Brain Res 606, 99-105 (1993)
[308]L. L. Guyot, F. G. Diaz, M. H. O’Regan, S. McLeod, H. Park and J. W. Phillis: Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett 299, 37-40 (2001)
[309]F. Mauler, T. Fahrig, E. Horvath and R. Jork: Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Brain Res 888, 150-157 (2001)
[310]J. G. Pilitsis, F. G. Diaz, M. H. O’Regan and J. W. Phillis: Differential effects of phospholipase inhibitors on free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res 951, 96-106 (2002)
[311]K. Narita, M. Kubota, M. Nakane, S. Kitahara, T. Nakagomi, A. Tamura, H. Hisaki, H. Shimasaki and N. Ueta: Therapeutic time window in the penumbra during permanent focal ischemia in rats: changes of free fatty acids and glycerophospholipids. Neurol Res 22, 393-400 (2000)
[312]D. Sun, D. Kintner, J. H. Fitzpatrick, S. E. Emoto, P. G. Braquet, N. G. Bazan and D. D. Gilboe: The effect of a free radical scavenger and platelet-activating factor antagonist on FFA accumulation in post-ischemic canine brain. Neurochem Res 19, 525-8 (1994)
[313]Y. Liu, S. Mituska, K. Hashizume, T. Hosaka and H. Nukui: The time course of glucose metabolism in rat cerebral ischemia with middle cerebral artery occlusion-reperfusion model and the effect of MK-801. Neurol Res, 18(6), 505-8 (1996)
[314]E. D. Hall: Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci 134, 79-83 (1995)
[315]R. Murin, A. Drgova, P. Kaplan, D. Dobrota and J. Lehotsky: Ischemia/Reperfusion-induced oxidative stress causes structural changes of brain membrane proteins and lipids. Gen Physiol Biophys 20, 431-8 (2001)
[316]E. McCracken, V. Valeriani, C. Simpson, T. Jover, J. McCulloch and D. Dewar: The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. J Cereb Blood Flow Metab 20, 1529-36 (2000)
[317]P. Ciceri, M. Rabuffetti, A. Monopoli and S. Nicosia: Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br J Pharmacol 133, 1323-9 (2001)
[318]F. Tegtmeier, C. Weber, U. Heister, I. Haker, D. Scheller, R. Nikolov and M. Holler: Eicosanoids in rat brain during ischemia and reperfusion--correlation to DC depolarization. J Cereb Blood Flow Metab 10, 358-64 (1990)
[319]M. Usui, T. Asano and K. Takakura: Identification and quantitative analysis of hydroxy-eicosatetraenoic acids in rat brains exposed to regional ischemia. Stroke 18, 490-4 (1987)
[320]Y. Tanaka, T. Omura, M. Fukasawa, N. Horiuchi, N. Miyata, T. Minagawa, S. Yoshida and S. Nakaike: Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. Neurosci Res 59, 475-80 (2007)
[321]N. C. Ward, K. D. Croft, D. Blacker, G. J. Hankey, A. Barden, T. A. Mori, I. B. Puddey and C. D. Beer: Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci 121, 501-7 (2011)
[322]Y. Tanaka, C. Koizumi, T. Tashiro, T. Susumu, M. Fukasawa, N. Horiuchi, T. Minagawa, T. Omura, N. Miyata and S. Yoshida: TS-011 improves neurological and functional outcomes after focal cerebral ischemia in rats. Stroke, (2007)
[323]T. Marumo, K. Eto, H. Wake, T. Omura and J. Nabekura: The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br J Pharmacol 161, 1391-402 (2010)
[324]S. M. Poloyac, Y. Zhang, R. R. Bies, P. M. Kochanek and S. H. Graham: Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J Cereb Blood Flow Metab 26, 1551-61 (2006)
[325]V. Randriamboavonjy, R. Busse and I. Fleming: 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 41, 801-6 (2003)
[326]C. W. Sun, J. R. Falck, D. R. Harder and R. J. Roman: Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33, 414-8 (1999)
[327]M. M. Muthalif, I. F. Benter, Z. Khandekar, L. Gaber, A. Estes, S. Malik, J. H. Parmentier, V. Manne and K. U. Malik: Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension 35, 457-63 (2000)
[328]M. M. Muthalif, N. A. Karzoun, L. Gaber, Z. Khandekar, I. F. Benter, A. E. Saeed, J. H. Parmentier, A. Estes and K. U. Malik: Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 36, 604-9 (2000)
[329]M. M. Muthalif, M. R. Uddin, S. Fatima, J. Parmentier, Z. Khandekar and K. U. Malik: Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells(1). Prostaglandins 65, 33-43 (2001)
[330]S. Nowicki, S. L. Chen, O. Aizman, X. J. Cheng, D. Li, C. Nowicki, A. Nairn, P. Greengard and A. Aperia: 20-Hydroxyeicosa-tetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+-ATPase. J Clin Invest 99, 1224-30 (1997)
[331]G. M. Chertow, E. Burdick, M. Honour, J. V. Bonventre and D. W. Bates: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16, 3365-70 (2005)
[332]N. Lameire, W. Van Biesen and R. Vanholder: The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2, 364-77 (2006)
[333]N. Lameire and R. Vanholder: Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol 12 Suppl 17, S20-32 (2001)
[334]K. Nithipatikom, E. R. Gross, M. P. Endsley, J. M. Moore, M. A. Isbell, J. R. Falck, W. B. Campbell and G. J. Gross: Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res 95, e65-71 (2004)
[335]R. J. Roman, T. Akbulut, F. Park and K. R. Regner: 20-HETE in acute kidney injury. Kidney Int 79, 10-3 (2011)
[336]J. M. Williams, A. Sarkis, K. M. Hoagland, K. Fredrich, R. P. Ryan, C. Moreno, B. Lopez, J. Lazar, F. J. Fenoy, M. Sharma, M. R. Garrett, H. J. Jacob and R. J. Roman: Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol 295, F1764-77 (2008)
[337]D. P. Basile, D. Donohoe, X. Cao and S. K. Van Why: Resistance to ischemic acute renal failure in the Brown Norway rat: a new model to study cytoprotection. Kidney Int 65, 2201-11 (2004)
[338]V. Nilakantan, C. Maenpaa, G. Jia, R. J. Roman and F. Park: 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 294, F562-70 (2008)
[339]A. O. Oyekan: Differential effects of 20-hydroxyeicosatetraenoic acid on intrarenal blood flow in the rat. J Pharmacol Exp Ther 313, 1289-95 (2005)
[340]T. Akbulut, K. R. Regner, R. J. Roman, E. D. Avner, J. R. Falck and F. Park: 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR-and c-Src-dependent mechanism. Am J Physiol 297, F662-F670 (2009)
[341]J. F. di Mari, R. Davis and R. L. Safirstein: MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol 277, F195-203 (1999)
[342]K. M. Park, A. Chen and J. V. Bonventre: Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem 276, 11870-6 (2001)
[343]H. L. Waller, S. J. Harper, S. A. Hosgood, A. Bagul, M. D. Kay, M. Kaushik, B. Yang, G. R. Bicknell and M. L. Nicholson: Differential expression of cytoprotective and apoptotic genes in an ischaemia-reperfusion isolated organ perfusion model of the transplanted kidney. Transpl Int 20, 625-31 (2007)
[344]J. Pratschke, S. Weiss, P. Neuhaus and A. Pascher: Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transpl Int 21, 512-22 (2008)
[345]L. H. Toledo-Pereyra, A. H. Toledo, J. Walsh and F. Lopez-Neblina: Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant 2, 174-7 (2004)
[346]D. Hernandez, S. Estupinan, G. Perez, M. Rufino, J. M. Gonzalez-Posada, D. Luis, P. Delgado, A. Rodriguez, D. Marrero, E. Porrini and A. Torres: Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transpl Int 21, 955-62 (2008)
[347]A. S. Weiss, J. Gralla, L. Chan, P. Klem and A. C. Wiseman: Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol 3, 1812-9 (2008)
[348]B. Dolegowska, W. Blogowski and L. Domanski: Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report. Transpl Int 22, 546-53 (2009)
[349]B. Dolegowska, W. Blogowski, K. Safranow, L. Domanski, K. Jakubowska and M. Olszewska: Lipoxygenase-derived hydroxyeicosatetraenoic acids--novel perioperative markers of early post-transplant allograft function? Nephrol Dial Transplant 25, 4061-7 (2010)
[350]E. R. Gross, K. Nithipatikom, A. K. Hsu, J. N. Peart, J. R. Falck, W. B. Campbell and G. J. Gross: Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol 37, 1245-9 (2004)
[351]K. Nithipatikom, R. F. DiCamelli, S. Kohler, R. J. Gumina, J. R. Falck, W. B. Campbell and G. J. Gross: Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem 292, 115-24 (2001)
[352]K. Nithipatikom, M. P. Endsley, J. M. Moore, M. A. Isbell, J. R. Falck, W. B. Campbell and G. J. Gross: Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol 290, H500-5 (2006)
[353]Y. Bao, X. Wang, W. Li, D. Huo, X. Shen, Y. Han, J. Tan, Q. Zeng and C. Sun: 20-Hydroxyeicosatetraenoic acid induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways. J Cardiovasc Pharmacol 57, 294-301 (2011)
[354]D. Mozaffarian, E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha, M. Cushman, S. de Ferranti, J. P. Despres, H. J. Fullerton, V. J. Howard, M. D. Huffman, S. E. Judd, B. M. Kissela, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, S. Liu, R. H. Mackey, D. B. Matchar, D. K. McGuire, E. R. Mohler, 3rd, C. S. Moy, P. Muntner, M. E. Mussolino, K. Nasir, R. W. Neumar, G. Nichol, L. Palaniappan, D. K. Pandey, M. J. Reeves, C. J. Rodriguez, P. D. Sorlie, J. Stein, A. Towfighi, T. N. Turan, S. S. Virani, J. Z. Willey, D. Woo, R. W. Yeh, M. B. Turner, C. American Heart Association Statistics and S. Stroke Statistics: Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 131, e29-322 (2015)
[355]B. N. Zordoky, M. E. Aboutabl and A. O. El-Kadi: Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos 36, 2277-86 (2008)
[356]H. N. Althurwi, O. H. Elshenawy and A. O. El-Kadi: Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol 63, 167-77 (2014)
[357]M. E. Aboutabl, B. N. Zordoky, B. D. Hammock and A. O. El-Kadi: Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J Cardiovasc Pharmacol 57, 273-81 (2011)
[358]M. E. Aboutabl, B. N. Zordoky and A. O. El-Kadi: 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158, 1808-19 (2009)
[359]S. Elkhatali, A. A. El-Sherbeni, O. H. Elshenawy, G. Abdelhamid and A. O. El-Kadi: 19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy. Toxicol Appl Pharmacol 289, 550-9 (2015)
[360]B. N. Zordoky and A. O. El-Kadi: Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 9, 122-8 (2008)
[361]B. N. Zordoky, A. Anwar-Mohamed, M. E. Aboutabl and A. O. El-Kadi: Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242, 38-46 (2010)
[362]Q. Zeng, Y. Han, Y. Bao, W. Li, X. Li, X. Shen, X. Wang, F. Yao, S. T. O’Rourke and C. Sun: 20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type Ca2+ channel via a PKC-dependent mechanism in cardiomyocytes. Am J Physiol Heart Circ Physiol 299, H1109-17 (2010)
[363]M. U. Moreno, G. San Jose, A. Pejenaute, M. F. Landecho, J. Diez, O. Beloqui, A. Fortuno and G. Zalba: Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1? Hypertension 63, 468-74 (2014)
[364]S. F. Steinberg: Cardiac actions of protein kinase C isoforms. Physiology 27, 130-9 (2012)
[365]G. W. Dorn, 2nd and T. Force: Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115, 527-37 (2005)
[366]T. Shinomura, Y. Asaoka, M. Oka, K. Yoshida and Y. Nishizuka: Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. Proc Natl Acad Sci U S A 88, 5149-53 (1991)
[367]H. Zhao, G. Qi, Y. Han, X. Shen, F. Yao, C. Xuan, Y. Gu, S. Y. Qian, Q. Zeng, S. T. O’Rourke and C. Sun: 20-Hydroxyeicosatetraenoic Acid Is a Key Mediator of Angiotensin II-induced Apoptosis in Cardiac Myocytes. J Cardiovasc Pharmacol 66, 86-95 (2015)
Article Metrics
Download
- Contents
Information
Download
Contents
Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
1 Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA
2 Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China
3 Department of General Medicine and Rehabilitation, Tohoku Medical and Pharmaceutical University School of Medicine, Sendai, Japan
4 Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Abstract
Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs). 20-HETE is a vasoconstrictor that depolarizes vascular smooth muscle cells by blocking K+ channels. EETs serve as endothelial derived hyperpolarizing factors. Inhibition of the formation of 20-HETE impairs the myogenic response and autoregulation of renal and cerebral blood flow. Changes in the formation of EETs and 20-HETE have been reported in hypertension and drugs that target these pathways alter blood pressure in animal models. Sequence variants in CYP4A11 and CYP4F2 that produce 20-HETE, UDP-glucuronosyl transferase involved in the biotransformation of 20-HETE and soluble epoxide hydrolase that inactivates EETs are associated with hypertension in human studies. 20-HETE contributes to the regulation of vascular hypertrophy, restenosis, angiogenesis and inflammation. It also promotes endothelial dysfunction and contributes to cerebral vasospasm and ischemia-reperfusion injury in the brain, kidney and heart. This review will focus on the role of 20-HETE in vascular dysfunction, inflammation, ischemic and hemorrhagic stroke and cardiac and renal ischemia reperfusion injury.
Keywords
- 20-HETE
- Cytochrome P450
- Vascular Smooth Muscle
- Endothelial Dysfunction
- Vascular Remodeling
- Vascular Inflammation
- Ischemia Reperfusion
- Stroke
- Review
References
- [1] D. Claar, T. V. Hartert and R. S. Peebles, Jr.: The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med 9, 55-72 (2015)
- [2] T. Shimizu: Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 49, 123-50 (2009)
- [3] R. C. Harris and M. Z. Zhang: Cyclooxygenase metabolites in the kidney. Compr Physiol 1, 1729-58 (2011)
- [4] V. Capra, M. Back, S. S. Barbieri, M. Camera, E. Tremoli and G. E. Rovati: Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 33, 364-438 (2013)
- [5] A. R. Morrison and N. Pascoe: Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proc Natl Acad Sci U S A 78, 7375-8 (1981)
- [6] E. H. Oliw, J. A. Lawson, A. R. Brash and J. A. Oates: Arachidonic acid metabolism in rabbit renal cortex. Formation of two novel dihydroxyeicosatrienoic acids. J Biol Chem 256, 9924-31 (1981)
- [7] W. B. Campbell, D. Gebremedhin, P. F. Pratt and D. R. Harder: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78, 415-23 (1996)
- [8] J. C. McGiff and J. Quilley: 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol 277, R607-23 (1999)
- [9] M. Rahman, J. T. Wright, Jr. and J. G. Douglas: The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Am J Hypertens 10, 356-65 (1997)
- [10] R. J. Roman and M. Alonso-Galicia: P-450 Eicosanoids: A novel Signaling Pathway Regulating Renal Function. News Physiol Sci 14, 238-242 (1999)
- [11] F. Fan, Y. Muroya and R. J. Roman: Cytochrome P450 eicosanoids in hypertension and renal disease. Curr Opin Nephrol Hypertens 24, 37-46 (2015)
- [12] D. R. Harder, N. J. Alkayed, A. R. Lange, D. Gebremedhin and R. J. Roman: Functional hyperemia in the brain: hypothesis for astrocyte-derived vasodilator metabolites. Stroke 29, 229-34 (1998)
- [13] D. R. Harder, D. Gebremedhin, J. Narayanan, C. Jefcoat, J. R. Falck, W. B. Campbell and R. Roman: Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol 266, H2098-2107 (1994)
- [14] E. Hill and R. C. Murphy: Quantitation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) produced by human polymorphonuclear leukocytes using electron capture ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 21, 249-53 (1992)
- [15] J. D. Imig, A. P. Zou, D. E. Stec, D. R. Harder, J. R. Falck and R. J. Roman: Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol 270, R217-27 (1996)
- [16] O. Ito, Y. Nakamura, L. Tan, T. Ishizuka, Y. Sasaki, N. Minami, M. Kanazawa, S. Ito, H. Sasano and M. Kohzuki: Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol Cell Biochem 284, 141-8 (2006)
- [17] R. J. Roman, K. G. Maier, C. W. Sun, D. R. Harder and M. Alonso-Galicia: Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 27, 855-65 (2000)
- [18] D. Zhu, R. M. Effros, D. R. Harder, R. J. Roman and E. R. Jacobs: Tissue sources of cytochrome P4504A and 20-HETE synthesis in rabbit lungs. Am J Respir Cell Mol Biol 19, 121-8 (1998)
- [19] K. Node, Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D. C. Zeldin and J. K. Liao: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-9 (1999)
- [20] M. M. Muthalif, I. F. Benter, N. Karzoun, S. Fatima, J. Harper, M. R. Uddin and K. U. Malik: 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci U S A 95, 12701-6 (1998)
- [21] M. R. Uddin, M. M. Muthalif, N. A. Karzoun, I. F. Benter and K. U. Malik: Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension 31, 242-7 (1998)
- [22] F. Lin, A. Rios, J. R. Falck, Y. Belosludtsev and M. L. Schwartzman: 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol 269, F806-16 (1995)
- [23] L. D. Orozco, H. Liu, E. Perkins, D. A. Johnson, B. B. Chen, F. Fan, R. C. Baker and R. J. Roman: 20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries. J Pharmacol Exp Ther 346, 67-74 (2013)
- [24] A. M. Guo, A. S. Arbab, J. R. Falck, P. Chen, P. A. Edwards, R. J. Roman and A. G. Scicli: Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther 321, 18-27 (2007)
- [25] R. J. Roman: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82, 131-85 (2002)
- [26] J. D. Imig: Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat 104-105, 2-7 (2013)
- [27] J. M. Williams, F. Fan, S. Murphy, C. Schreck, J. Lazar, H. J. Jacob and R. J. Roman: Role of 20-HETE in the antihypertensive effect of transfer of chromosome 5 from Brown Norway to Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 302, R1209-18 (2012)
- [28] J. M. Lasker, W. B. Chen, I. Wolf, B. P. Bloswick, P. D. Wilson and P. K. Powell: Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 275, 4118-26 (2000)
- [29] P. K. Powell, I. Wolf, R. Jin and J. M. Lasker: Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285, 1327-36 (1998)
- [30] V. Hirani, A. Yarovoy, A. Kozeska, R. P. Magnusson and J. M. Lasker: Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies. Arch Biochem Biophys 478, 59-68 (2008)
- [31] J. V. Gainer, A. Bellamine, E. P. Dawson, K. E. Womble, S. W. Grant, Y. Wang, L. A. Cupples, C. Y. Guo, S. Demissie, C. J. O’Donnell, N. J. Brown, M. R. Waterman and J. H. Capdevila: Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111, 63-9 (2005)
- [32] Y. Kikuta, E. Kusunose, K. Endo, S. Yamamoto, K. Sogawa, Y. Fujii-Kuriyama and M. Kusunose: A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase. J Biol Chem 268, 9376-80 (1993)
- [33] F. Fan, A. M. Geurts, S. R. Murphy, M. R. Pabbidi, H. J. Jacob and R. J. Roman: Impaired myogenic response and autoregulation of cerebral blood flow is rescued in CYP4A1 transgenic Dahl salt-sensitive rat. Am J Physiol Regul Integr Comp Physiol 308, R379-90 (2015)
- [34] J. P. Hardwick, B. J. Song, E. Huberman and F. J. Gonzalez: Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid omega-hydroxylase (cytochrome P-450 LA omega). Identification of a new cytochrome P-450 gene family. J Biol Chem 262, 801-10 (1987)
- [35] X. Nguyen, M. H. Wang, K. M. Reddy, J. R. Falck and M. L. Schwartzman: Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol 276, R1691-700 (1999)
- [36] H. Kawashima, E. Kusunose, C. M. Thompson and H. W. Strobel: Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 347, 148-54 (1997)
- [37] H. Kawashima and H. W. Strobel: cDNA cloning of three new forms of rat brain cytochrome P450 belonging to the CYP4F subfamily. Biochem Biophys Res Commun 217, 1137-44 (1995)
- [38] Y. Kikuta, E. Kusunose, M. Ito and M. Kusunose: Purification and characterization of recombinant rat hepatic CYP4F1. Arch Biochem Biophys 369, 193-6 (1999)
- [39] F. Xu, J. R. Falck, P. R. Ortiz de Montellano and D. L. Kroetz: Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther 308, 887-95 (2004)
- [40] J. Bylund, A. G. Harder, K. G. Maier, R. J. Roman and D. R. Harder: Leukotriene B4 omega-side chain hydroxylation by CYP4F5 and CYP4F6. Arch Biochem Biophys 412, 34-41 (2003)
- [41] V. R. Holla, F. Adas, J. D. Imig, X. Zhao, E. Price, Jr., N. Olsen, W. J. Kovacs, M. A. Magnuson, D. S. Keeney, M. D. Breyer, J. R. Falck, M. R. Waterman and J. H. Capdevila: Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A 98, 5211-6 (2001)
- [42] D. N. Muller, C. Schmidt, E. Barbosa-Sicard, M. Wellner, V. Gross, H. Hercule, M. Markovic, H. Honeck, F. C. Luft and W. H. Schunck: Mouse Cyp4a isoforms: enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403, 109-18 (2007)
- [43] M. L. Schwartzman, J. R. Falck, P. Yadagiri and B. Escalante: Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J Biol Chem 264, 11658-62 (1989)
- [44] B. Escalante, W. C. Sessa, J. R. Falck, P. Yadagiri and M. L. Schwartzman: Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J Pharmacol Exp Ther 248, 229-32 (1989)
- [45] X. H. Collins, S. D. Harmon, T. L. Kaduce, K. B. Berst, X. Fang, S. A. Moore, T. V. Raju, J. R. Falck, N. L. Weintraub, G. Duester, B. V. Plapp and A. A. Spector: Omega-oxidation of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4. J Biol Chem 280, 33157-64 (2005)
- [46] Y. B. Jarrar, E. Y. Cha, K. A. Seo, J. L. Ghim, H. J. Kim, D. H. Kim, S. J. Lee and J. G. Shin: Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. J Lipid Res 55, 2334-42 (2014)
- [47] K. M. Knights, A. Rowland and J. O. Miners: Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 76, 587-602 (2013)
- [48] A. W. Dreisbach, S. V. Smith, P. B. Kyle, M. Ramaiah, M. Amenuke, M. R. Garrett, S. T. Lirette, M. E. Griswold and R. J. Roman: Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease. Prostaglandins Other Lipid Mediat 113-115, 45-51 (2014)
- [49] J. S. Marji, M. H. Wang and M. Laniado-Schwartzman: Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries. Am J Physiol Renal Physiol 283, F60-7 (2002)
- [50] M. Renic, J. A. Klaus, T. Omura, N. Kawashima, M. Onishi, N. Miyata, R. C. Koehler, D. R. Harder and R. J. Roman: Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 29, 629-39 (2009)
- [51] M. A. Carroll, R. Kemp, M. K. Cheng and J. C. McGiff: Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med Sci Monit 7, 567-72 (2001)
- [52] F. Fan, C. W. Sun, K. G. Maier, J. M. Williams, M. R. Pabbidi, S. P. Didion, J. R. Falck, J. Zhuo and R. J. Roman: 20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K+ channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels. PLoS One 8, e82482 (2013)
- [53] E. K. Birks, M. Bousamra, K. Presberg, J. A. Marsh, R. M. Effros and E. R. Jacobs: Human pulmonary arteries dilate to 20-HETE, an endogenous eicosanoid of lung tissue. Am J Physiol 272, L823-9 (1997)
- [54] A. Yaghi, C. D. Webb, J. A. Scott, S. Mehta, J. R. Bend and D. G. McCormack: Cytochrome P450 metabolites of arachidonic acid but not cyclooxygenase-2 metabolites contribute to the pulmonary vascular hyporeactivity in rats with acute Pseudomonas pneumonia. J Pharmacol Exp Ther 297, 479-88 (2001)
- [55] J. S. Wang, H. Singh, F. Zhang, T. Ishizuka, H. Deng, R. Kemp, M. S. Wolin, T. H. Hintze, N. G. Abraham, A. Nasjletti and M. Laniado-Schwartzman: Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 98, 962-9 (2006)
- [56] K. Inoue, K. Sodhi, N. Puri, K. H. Gotlinger, J. Cao, R. Rezzani, J. R. Falck, N. G. Abraham and M. Laniado-Schwartzman: Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am J Physiol Renal Physiol 297, F875-84 (2009)
- [57] H. Singh, J. Cheng, H. Deng, R. Kemp, T. Ishizuka, A. Nasjletti and M. L. Schwartzman: Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50, 123-9 (2007)
- [58] C. C. Wu, J. Cheng, F. F. Zhang, K. H. Gotlinger, M. Kelkar, Y. Zhang, J. L. Jat, J. R. Falck and M. L. Schwartzman: Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: role of inhibitor of kappaB Kinase. Hypertension 57, 788-94 (2011)
- [59] H. Singh and M. L. Schwartzman: Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep 60, 29-37 (2008)
- [60] M. Renic, S. N. Kumar, D. Gebremedhin, M. A. Florence, N. Z. Gerges, J. R. Falck, D. R. Harder and R. J. Roman: Protective effect of 20-HETE inhibition in a model of oxygen-glucose deprivation in hippocampal slice cultures. Am J Physiol Heart Circ Physiol 302, H1285-93 (2012)
- [61] B. A. MacVicar and E. A. Newman: Astrocyte regulation of blood flow in the brain. Cold Spring Harb Perspect Biol 7 (2015)
- [62] M. H. Yousif, I. F. Benter and R. J. Roman: Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton Autacoid Pharmacol 29, 33-41 (2009)
- [63] A. Anwar-mohamed, B. N. Zordoky, M. E. Aboutabl and A. O. El-Kadi: Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 61, 410-8 (2010)
- [64] J. Antoun, S. Goulitquer, Y. Amet, Y. Dreano, J. P. Salaun, L. Corcos and E. Plee-Gautier: CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis. J Lipid Res 49, 2135-41 (2008)
- [65] T. W. Wilson, M. Alonso-Galicia and R. J. Roman: Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31, 225-31 (1998)
- [66] O. Ito, M. Alonso-Galicia, K. A. Hopp and R. J. Roman: Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol 274, F395-404 (1998)
- [67] O. Ito and R. J. Roman: Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol 276, R1749-57 (1999)
- [68] K. Omata, N. G. Abraham and M. L. Schwartzman: Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. Am J Physiol 262, F591-9 (1992)
- [69] I. J. Tsai, K. D. Croft, I. B. Puddey, L. J. Beilin and A. Barden: 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am J Physiol Heart Circ Physiol 300, H1194-200 (2011)
- [70] E. Hill, F. Fitzpatrick and R. C. Murphy: Biological activity and metabolism of 20-hydroxyeicosatetraenoic acid in the human platelet. Br J Pharmacol 106, 267-74 (1992)
- [71] D. R. Harder, R. J. Roman, D. Gebremedhin, E. K. Birks and A. R. Lange: A common pathway for regulation of nutritive blood flow to the brain: arterial muscle membrane potential and cytochrome P450 metabolites. Acta Physiol Scand 164, 527-32 (1998)
- [72] D. Zhu, M. Bousamra, 2nd, D. C. Zeldin, J. R. Falck, M. Townsley, D. R. Harder, R. J. Roman and E. R. Jacobs: Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 278, L335-43 (2000)
- [73] D. C. Zeldin, J. D. Plitman, J. Kobayashi, R. F. Miller, J. R. Snapper, J. R. Falck, J. L. Szarek, R. M. Philpot and J. H. Capdevila: The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest 95, 2150-60 (1995)
- [74] M. Rosolowsky and W. B. Campbell: Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 264, H327-35 (1993)
- [75] M. Rosolowsky, J. R. Falck, J. T. Willerson and W. B. Campbell: Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res 66, 608-21 (1990)
- [76] D. H. Munzenmaier and D. R. Harder: Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 278, H1163-7 (2000)
- [77] N. J. Alkayed, J. Narayanan, D. Gebremedhin, M. Medhora, R. J. Roman and D. R. Harder: Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke 27, 971-9 (1996)
- [78] S. C. Amruthesh, M. F. Boerschel, J. S. McKinney, K. A. Willoughby and E. F. Ellis: Metabolism of arachidonic acid to epoxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and prostaglandins in cultured rat hippocampal astrocytes. J Neurochem 61, 150-9 (1993)
- [79] S. Wu, W. Chen, E. Murphy, S. Gabel, K. B. Tomer, J. Foley, C. Steenbergen, J. R. Falck, C. R. Moomaw and D. C. Zeldin: Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272, 12551-9 (1997)
- [80] S. Wu, C. R. Moomaw, K. B. Tomer, J. R. Falck and D. C. Zeldin: Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271, 3460-8 (1996)
- [81] Q. Y. Zhang, G. Raner, X. Ding, D. Dunbar, M. J. Coon and L. S. Kaminsky: Characterization of the cytochrome P450 CYP2J4: expression in rat small intestine and role in retinoic acid biotransformation from retinal. Arch Biochem Biophys 353, 257-64 (1998)
- [82] D. C. Zeldin, J. Foley, J. E. Boyle, C. R. Moomaw, K. B. Tomer, C. Parker, C. Steenbergen and S. Wu: Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138, 1338-46 (1997)
- [83] M. Schwartzman, N. R. Ferreri, M. A. Carroll, E. Songu-Mize and J. C. McGiff: Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature 314, 620-2 (1985)
- [84] R. Quigley, M. Baum, K. M. Reddy, J. C. Griener and J. R. Falck: Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol 278, F949-53 (2000)
- [85] O. Ito and R. J. Roman: Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension 33, 419-23 (1999)
- [86] F. Park, W. E. Sweeney, G. Jia, T. Akbulut, B. Mueller, J. R. Falck, S. Birudaraju, R. J. Roman and E. D. Avner: Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD. Am J Physiol 296, F575-F582 (2009)
- [87] F. Park, W. E. Sweeney, G. Jia, R. J. Roman and E. D. Avner: 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease. JASN 19, 1929-1939 (2008)
- [88] J. Klawitter, J. Klawitter, K. McFann, A. T. Pennington, K. Z. Abebe, G. Brosnahan, M. A. Cadnapaphornchai, M. Chonchol, B. Gitomer, U. Christians and R. W. Schrier: Bioactive lipid mediators in polycystic kidney disease. J Lipid Res 55, 1139-1149 (2013)
- [89] Y. H. Ma, M. L. Schwartzman and R. J. Roman: Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol 267, R579-89 (1994)
- [90] H. Honeck, V. Gross, B. Erdmann, E. Kargel, R. Neunaber, A. F. Milia, W. Schneider, F. C. Luft and W. H. Schunck: Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension 36, 610-6 (2000)
- [91] J. D. Imig, J. R. Falck, D. Gebremedhin, D. R. Harder and R. J. Roman: Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. Hypertension 22, 357-64 (1993)
- [92] D. L. Kroetz, L. M. Huse, A. Thuresson and M. P. Grillo: Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol 52, 362-72 (1997)
- [93] C. L. Laffer, M. Laniado-Schwartzman, M. H. Wang, A. Nasjletti and F. Elijovich: 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension. Hypertension 41, 703-8 (2003)
- [94] I. Messer-Letienne, N. Bernard, R. J. Roman, J. Sassard and D. Benzoni: Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. Am J Hypertens 12, 398-404 (1999)
- [95] I. Messer-Letienne, N. Bernard, R. J. Roman, J. Sassard and D. Benzoni: 20-Hydroxyeicosatetraenoic acid and renal function in Lyon hypertensive rats. Eur J Pharmacol 378, 291-7 (1999)
- [96] D. Sacerdoti, N. G. Abraham, J. C. McGiff and M. L. Schwartzman: Renal cytochrome P-450-dependent metabolism of arachidonic acid in spontaneously hypertensive rats. Biochem Pharmacol 37, 521-7 (1988)
- [97] K. Nakagawa, J. S. Marji, M. L. Schwartzman, M. R. Waterman and J. H. Capdevila: Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol Regul Integr Comp Physiol 284, R1055-62 (2003)
- [98] B. Zhang, X. Yi, C. Wang, D. Liao, J. Lin and L. Chi: Cytochrome 4A11 Genetic Polymorphisms Increase Susceptibility to Ischemic Stroke and Associate with Atherothrombotic Events After Stroke in Chinese. Genet Test Mol Biomarkers 19, 235-41 (2015)
- [99] H. Ding, G. Cui, L. Zhang, Y. Xu, X. Bao, Y. Tu, B. Wu, Q. Wang, R. Hui, W. Wang, R. T. Dackor, G. E. Kissling, D. C. Zeldin and D. W. Wang: Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics 20, 187-94 (2010)
- [100] F. Elijovich and C. L. Laffer: The relationship between CYP4A11 and human hypertension. J Hypertens 26, 1712-4 (2008)
- [101] Z. Fu, Y. Ma, X. Xie, D. Huang, H. Yang, T. Nakayama and N. Sato: A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 19, 60-5 (2013)
- [102] Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, K. Matsumoto, Y. Ozawa and Y. Ma: Haplotype-based case study of human CYP4A11 gene and cerebral infarction in Japanese subject. Endocrine 33, 215-22 (2008)
- [103] Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, Y. Ozawa and Y. Ma: A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men. J Hypertens 26, 453-61 (2008)
- [104] Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, Y. Ozawa and Y. Ma: Haplotype-based case-control study of CYP4A11 gene and myocardial infarction. Hereditas 149, 91-8 (2012)
- [105] Z. Fu, H. Yang, Y. Ma, D. Huang, X. Xie, Y. Zheng, Q. Zhu and T. Nakayama: Haplotype study of the CYP4A11 gene and coronary artery disease in Han and Uygur populations in China. Gene 512, 510-6 (2013)
- [106] J. V. Gainer, M. S. Lipkowitz, C. Yu, M. R. Waterman, E. P. Dawson, J. H. Capdevila, N. J. Brown and A. S. Group: Association of a CYP4A11 variant and blood pressure in black men. J Am Soc Nephrol 19, 1606-12 (2008)
- [107] C. L. Laffer, J. V. Gainer, M. R. Waterman, J. H. Capdevila, M. Laniado-Schwartzman, A. Nasjletti, N. J. Brown and F. Elijovich: The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 51, 767-72 (2008)
- [108] J. Q. Liang, M. R. Yan, L. Yang, Q. Suyila, H. W. Cui and X. L. Su: Association of a CYP4A11 polymorphism and hypertension in the Mongolian and Han populations of China. Genet Mol Res 13, 508-17 (2014)
- [109] K. Sugimoto, H. Akasaka, T. Katsuya, K. Node, T. Fujisawa, I. Shimaoka, O. Yasuda, M. Ohishi, T. Ogihara, K. Shimamoto and H. Rakugi: A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population. Hypertension 52, 1142-8 (2008)
- [110] N. C. Ward, I. J. Tsai, A. Barden, F. M. van Bockxmeer, I. B. Puddey, J. M. Hodgson and K. D. Croft: Asingle nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 51, 1393-8 (2008)
- [111] D. E. Stec, R. J. Roman, A. Flasch and M. J. Rieder: Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 30, 74-81 (2007)
- [112] N. C. Ward, K. D. Croft, I. B. Puddey, M. Phillips, F. van Bockxmeer, L. J. Beilin and A. E. Barden: The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J Hypertens 32, 1495-502 (2014)
- [113] S. Deng, G. Zhu, F. Liu, H. Zhang, X. Qin, L. Li and H. Zhiyi: CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 34, 664-8 (2010)
- [114] C. Fava, M. Montagnana, P. Almgren, L. Rosberg, G. Lippi, B. Hedblad, G. Engstrom, G. Berglund, P. Minuz and O. Melander: The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52, 373-80 (2008)
- [115] Z. Fu, T. Nakayama, N. Sato, Y. Izumi, Y. Kasamaki, A. Shindo, M. Ohta, M. Soma, N. Aoi, M. Sato, K. Matsumoto, Y. Ozawa and Y. Ma: A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens 21, 1216-23 (2008)
- [116] N. Miyata and R. J. Roman: Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 41, 175-93 (2005)
- [117] C. C. Wu, T. Gupta, V. Garcia, Y. Ding and M. L. Schwartzman: 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 22, 1-12 (2014)
- [118] S. L. Hoopes, V. Garcia, M. L. Edin, M. L. Schwartzman and D. C. Zeldin: Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat 120, 9-16 (2015)
- [119] J. M. Williams, S. Murphy, M. Burke and R. J. Roman: 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 56, 336-44 (2010)
- [120] A. H. Khan, J. R. Falck, V. L. Manthati, W. B. Campbell and J. D. Imig: Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Front Pharmacol 5, 216 (2014)
- [121] J. D. Imig and M. A. Hye Khan: Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. Compr Physiol 6, 423-41 (2015)
- [122] F. Kehl, L. Cambj-Sapunar, K. G. Maier, N. Miyata, S. Kametani, H. Okamoto, A. G. Hudetz, M. L. Schulte, D. Zagorac, D. R. Harder and R. J. Roman: 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol Heart Circ Physiol 282, H1556-65 (2002)
- [123] T. Kawasaki, T. Marumo, K. Shirakami, T. Mori, H. Doi, M. Suzuki, Y. Watanabe, S. Chaki, A. Nakazato, Y. Ago, H. Hashimoto, T. Matsuda, A. Baba and H. Onoe: Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor. J Cereb Blood Flow Metab 32, 1737-46 (2012)
- [124] L. Hacein-Bey, D. R. Harder, H. T. Meier, P. N. Varelas, N. Miyata, K. K. Lauer, J. F. Cusick and R. J. Roman: Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol 27, 1350-4 (2006)
- [125] X. Y. Yi, D. X. Liao, C. Wang, W. Cheng, X. Q. Fu and B. Zhang: Cytochrome P450 Genetic Variants and Their Metabolite Levels Associated with Plaque Stability in Patients with Ischemic Stroke. J Atheroscler Thromb (2015)
- [126] Y. Muroya, F. Fan, K. R. Regner, J. R. Falck, M. R. Garrett, L. A. Juncos and R. J. Roman: Deficiency in the Formation of 20-Hydroxyeicosatetraenoic Acid Enhances Renal Ischemia-Reperfusion Injury. J Am Soc Nephrol 26, 2460-9 (2015)
- [127] K. R. Regner, A. Zuk, S. K. Van Why, B. D. Shames, R. P. Ryan, J. R. Falck, V. L. Manthati, M. E. McMullen, S. R. Ledbetter and R. J. Roman: Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int 75, 511-7 (2009)
- [128] F. Catella, J. A. Lawson, D. J. Fitzgerald and G. A. FitzGerald: Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A 87, 5893-7 (1990)
- [129] D. Sacerdoti, M. Balazy, P. Angeli, A. Gatta and J. C. McGiff: Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest 100, 1264-70 (1997)
- [130] H. N. Althurwi, Z. H. Maayah, O. H. Elshenawy and A. O. El-Kadi: Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol. Drug Metab Dispos 43, 1254-66 (2015)
- [131] Y. Han, H. Zhao, H. Tang, X. Li, J. Tan, Q. Zeng and C. Sun: 20-Hydroxyeicosatetraenoic acid mediates isolated heart ischemia/reperfusion injury by increasing NADPH oxidase-derived reactive oxygen species production. Circ J 77, 1807-16 (2013)
- [132] B. Tunctan, B. Korkmaz, C. K. Buharalioglu, S. S. Firat, S. Anjaiah, J. Falck, R. J. Roman and K. U. Malik: A 20-hydroxyeicosatetraenoic acid agonist, N-(20-hydroxyeicosa-5(Z),14(Z)-dienoyl)glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock 30, 329-35 (2008)
- [133] A. N. Sari, B. Korkmaz, M. S. Serin, M. Kacan, D. Unsal, C. K. Buharalioglu, S. Sahan Firat, V. L. Manthati, J. R. Falck, K. U. Malik and B. Tunctan: Effects of 5,14-HEDGE, a 20-HETE mimetic, on lipopolysaccharide-induced changes in MyD88/TAK1/IKKbeta/IkappaB-alpha/NF-kappaB pathway and circulating miR-150, miR-223, and miR-297 levels in a rat model of septic shock. Inflamm Res 63, 741-56 (2014)
- [134] M. R. Metea and E. A. Newman: Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci 26, 2862-70 (2006)
- [135] A. P. Zou, J. T. Fleming, J. R. Falck, E. R. Jacobs, D. Gebremedhin, D. R. Harder and R. J. Roman: 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. Am J Physiol 270, R228-37 (1996)
- [136] D. Gebremedhin, A. R. Lange, J. Narayanan, M. R. Aebly, E. R. Jacobs and D. R. Harder: Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J Physiol 507, 771-81 (1998)
- [137] N. Basora, G. Boulay, L. Bilodeau, E. Rousseau and M. D. Payet: 20-hydroxyeicosatetraenoic acid (20-HETE) activates mouse TRPC6 channels expressed in HEK293 cells. J Biol Chem 278, 31709-16 (2003)
- [138] J. E. Brayden, S. Earley, M. T. Nelson and S. Reading: Transient receptor potential (TRP) channels, vascular tone and autoregulation of cerebral blood flow. Clin Exp Pharmacol Physiol 35, 1116-20 (2008)
- [139] H. Wen, J. Ostman, K. J. Bubb, C. Panayiotou, J. V. Priestley, M. D. Baker and A. Ahluwalia: 20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 287, 13868-76 (2012)
- [140] D. Gebremedhin, A. R. Lange, T. F. Lowry, M. R. Taheri, E. K. Birks, A. G. Hudetz, J. Narayanan, J. R. Falck, H. Okamoto, R. J. Roman, K. Nithipatikom, W. B. Campbell and D. R. Harder: Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 87, 60-5 (2000)
- [141] Y. Ge, S. R. Murphy, Y. Lu, J. Falck, R. Liu and R. J. Roman: Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles. Prostaglandins Other Lipid Mediat 102-103, 42-8 (2013)
- [142] Y. Ren, M. A. D’Ambrosio, J. L. Garvin, E. L. Peterson and O. A. Carretero: Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. Am J Physiol Renal Physiol 307, F533-8 (2014)
- [143] A. P. Zou, J. D. Imig, M. Kaldunski, P. R. Ortiz de Montellano, Z. Sui and R. J. Roman: Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol 266, F275-82 (1994)
- [144] Y. Ge, S. R. Murphy, F. Fan, J. M. Williams, J. R. Falck, R. Liu and R. J. Roman: Role of 20-HETE in the impaired myogenic and TGF responses of the Af-Art of Dahl salt-sensitive rats. Am J Physiol 307, F509-15 (2014)
- [145] A. P. Zou, J. D. Imig, P. R. Ortiz de Montellano, Z. Sui, J. R. Falck and R. J. Roman: Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 266, F934-41 (1994)
- [146] F. Fan, Y. Ge, S. Murphy, A. Geurts, H. Jacob and R. Roman: CYP4A1 transgenic rats generated using Sleeping Beauty transposon system restores the impaired myogenic responses in the afferent arteriole of Dahl S rats. (Abstract) Hypertens 62, A39 (2013)
- [147] S. Murphy, F. Fan, R. Baker, A. Guerts, H. Jacob and R. J. Roman: Upregulation of Renal Medullary 20-HETE Production Opposes the Development of Hypertension in Sleeping Beauty Transposon CYP4A1 Transgenic Dahl S rats. FASEB J, (2012)
- [148] Y. Chen, M. Medhora, J. R. Falck, K. A. Pritchard, Jr. and E. R. Jacobs: Mechanisms of activation of eNOS by 20-HETE and VEGF in bovine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 291, L378-85 (2006)
- [149] D. Zhu, C. Zhang, M. Medhora and E. R. Jacobs: CYP4A mRNA, protein, and product in rat lungs: novel localization in vascular endothelium. J Appl Physiol, 93, 330-7 (2002)
- [150] P. F. Pratt, J. R. Falck, K. M. Reddy, J. B. Kurian and W. B. Campbell: 20-HETE relaxes bovine coronary arteries through the release of prostacyclin. Hypertension 31, 237-41 (1998)
- [151] M. Alonso-Galicia, J. R. Falck, K. M. Reddy and R. J. Roman: 20-HETE agonists and antagonists in the renal circulation. Am J Physiol 277, F790-F796 (1999)
- [152] M. Yu, M. Alonso-Galicia, C. W. Sun, R. J. Roman, N. Ono, H. Hirano, T. Ishimoto, Y. K. Reddy, K. R. Katipally, K. M. Reddy, V. R. Gopal, J. Yu, M. Takhi and J. R. Falck: 20-hydroxyeicosatetraenoic acid (20-HETE): structural determinants for renal vasoconstriction. Bioorg Med Chem 11, 2803-21 (2003)
- [153] P. R. Ortiz de Montellano and N. O. Reich: Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J Biol Chem 259, 4136-41 (1984)
- [154] A.-P. Zou, Y.-H. Ma, Z.-H. Sui, P. O. De Montellano, J. E. Clark, B. S. Masters and R. J. Roman: Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J JPharmacol Exp Ther 268, 474-481 (1994)
- [155] M. Alonso-Galicia, H. A. Drummond, K. K. Reddy, J. R. Falck and R. J. Roman: Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29, 320-5 (1997)
- [156] M. H. Wang, E. Brand-Schieber, B. A. Zand, X. Nguyen, J. R. Falck, N. Balu and M. L. Schwartzman: Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284, 966-73 (1998)
- [157] N. Miyata, K. Taniguchi, T. Seki, T. Ishimoto, M. Sato-Watanabe, Y. Yasuda, M. Doi, S. Kametani, Y. Tomishima, T. Ueki, M. Sato and K. Kameo: HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133, 325-9 (2001)
- [158] T. Omura, Y. Tanaka, N. Miyata, C. Koizumi, T. Sakurai, M. Fukasawa, K. Hachiuma, T. Minagawa, T. Susumu, S. Yoshida, S. Nakaike, S. Okuyama, D. R. Harder and R. J. Roman: Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 37, 1307-13 (2006)
- [159] M. Sato, T. Ishii, Y. Kobayashi-Matsunaga, H. Amada, K. Taniguchi, N. Miyata and K. Kameo: Discovery of a N’-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett 11, 2993-5 (2001)
- [160] K. M. Hoagland, A. K. Flasch and R. J. Roman: Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42, 669-673 (2003)
- [161] J. M. Williams, A. Sarkis, B. Lopez, R. P. Ryan, A. K. Flasch and R. J. Roman: Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension 49, 687-94 (2007)
- [162] V. G. Pandey, V. Garcia, G. Joseph, F. F. Zhang, B. Shkolnik, P. Mishra, J. R. Falck, J. Capdevila and M. L. Schwartzman: 20-SOLA, a novel water-soluble 20-HETE antagonist, elicits natriuresis and abrogates hypertension in CYP4A14 knockout mice. Hypertension 64, A047 (2014)
- [163] V. Garcia, B. Shkolnik, V. Pandey, J. Capdevila, J. Falck and M. Schwartzman: 20-SOLA, a Novel Water Soluble 20-HETE Antagonist, Reduces Blood Pressure Through Regulation of Vascular ACE Expression via an IKK Dependent Pathway. FASEB J 29, 647.9. (2015)
- [164] J. Deanfield, A. Donald, C. Ferri, C. Giannattasio, J. Halcox, S. Halligan, A. Lerman, G. Mancia, J. J. Oliver, A. C. Pessina, D. Rizzoni, G. P. Rossi, A. Salvetti, E. L. Schiffrin, S. Taddei, D. J. Webb, E. Working Group on and H. Endothelial Factors of the European Society of: Endothelial function and dysfunction. PartI: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23, 7-17 (2005)
- [165] J. Cheng, J. S. Ou, H. Singh, J. R. Falck, D. Narsimhaswamy, K. A. Pritchard, Jr. and M. L. Schwartzman: 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol 294, H1018-26 (2008)
- [166] J. Cheng, C. C. Wu, K. H. Gotlinger, F. Zhang, J. R. Falck, D. Narsimhaswamy and M. L. Schwartzman: 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 332, 57-65 (2010)
- [167] P. Toth, A. Csiszar, D. Sosnowska, Z. Tucsek, P. Cseplo, Z. Springo, S. Tarantini, W. E. Sonntag, Z. Ungvari and A. Koller: Treatment with the cytochrome P450 omega-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats. Br J Pharmacol 168, 1878-88 (2013)
- [168] K. M. Dunn, M. Renic, A. K. Flasch, D. R. Harder, J. Falck and R. J. Roman: Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol, 295, H2455-65 (2008)
- [169] M. L. Schwartzman, J. L. da Silva, F. Lin, M. Nishimura and N. G. Abraham: Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron 73, 652-63 (1996)
- [170] A. Blanton, R. Nsaif, H. Hercule and A. Oyekan: Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypertens 24, 1865-72 (2006)
- [171] P. Fidelis, L. Wilson, K. Thomas, M. Villalobos and A. O. Oyekan: Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med, 235, 1365-74 (2010)
- [172] C. C. Wu, S. Mei, J. Cheng, Y. Ding, A. Weidenhammer, V. Garcia, F. Zhang, K. Gotlinger, V. L. Manthati, J. R. Falck, J. H. Capdevila and M. L. Schwartzman: Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol 24, 1288-96 (2013)
- [173] T. Ishizuka, J. Cheng, H. Singh, M. D. Vitto, V. L. Manthati, J. R. Falck and M. Laniado-Schwartzman: 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 324, 103-10 (2008)
- [174] R. N. Schuck, K. N. Theken, M. L. Edin, M. Caughey, A. Bass, K. Ellis, B. Tran, S. Steele, B. P. Simmons, F. B. Lih, K. B. Tomer, M. C. Wu, A. L. Hinderliter, G. A. Stouffer, D. C. Zeldin and C. R. Lee: Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis 227, 442-8 (2013)
- [175] N. C. Ward, I. B. Puddey, J. M. Hodgson, L. J. Beilin and K. D. Croft: Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med 38, 1032-6 (2005)
- [176] N. C. Ward, J. Rivera, J. Hodgson, I. B. Puddey, L. J. Beilin, J. R. Falck and K. D. Croft: Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110, 438-43 (2004)
- [177] J. Wang, H. Li, J. He, B. Li, Q. Bao, X. Zhang, Z. Lv, Y. Zhang, J. Han, D. Ai and Y. Zhu: 20-Hydroxyeicosatetraenoic acid involved in endothelial activation and thrombosis. Am J Physiol Heart Circ Physiol 308, H1359-67 (2015)
- [178] N. F. Renna: Oxidative stress, vascular remodeling, and vascular inflammation in hypertension. Int J Hypertens 710136 (2013).
- [179] N. F. Renna, N. de Las Heras and R. M. Miatello: Pathophysiology of vascular remodeling in hypertension. Int J Hypertens 808353 (2013)
- [180] J. C. McGrath, C. Deighan, A. M. Briones, M. M. Shafaroudi, M. McBride, J. Adler, S. M. Arribas, E. Vila and C. J. Daly: New aspects of vascular remodelling: the involvement of all vascular cell types. Exp Physiol 90, 469-75 (2005)
- [181] B. L. Langille: Remodeling of developing and mature arteries: endothelium, smooth muscle, and matrix. J Cardiovasc Pharmacol 21, S11-7 (1993)
- [182] J. H. Parmentier, M. M. Muthalif, A. T. Nishimoto and K. U. Malik: 20-Hydroxyeicosatetraenoic acid mediates angiotensin ii-induced phospholipase d activation in vascular smooth muscle cells. Hypertension 37, 623-9 (2001)
- [183] D. E. Stec, K. P. Gannon, J. S. Beaird and H. A. Drummond: 20-Hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem 19, 121-8 (2007)
- [184] A. M. Guo, B. Janic, J. Sheng, J. R. Falck, R. J. Roman, P. A. Edwards, A. S. Arbab and A. G. Scicli: The cytochrome P4504A/F-20-hydroxyeicosatetraenoic acid system: a regulator of endothelial precursor cells derived from human umbilical cord blood. J Pharmacol Exp Ther 338, 421-9 (2011)
- [185] A. M. Guo, G. Scicli, J. Sheng, J. C. Falck, P. A. Edwards and A. G. Scicli: 20-HETE can act as a nonhypoxic regulator of HIF-1alpha in human microvascular endothelial cells. Am J Physiol Heart Circ Physiol 297, H602-13 (2009)
- [186] J. Cheng, M. L. Edin, S. L. Hoopes, H. Li, J. A. Bradbury, J. P. Graves, L. M. DeGraff, F. B. Lih, V. Garcia, J. S. Shaik, K. B. Tomer, G. P. Flake, J. R. Falck, C. R. Lee, S. M. Poloyac, M. L. Schwartzman and D. C. Zeldin: Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB J 28, 2915-31 (2014)
- [187] L. Chen, R. Ackerman, M. Saleh, K. H. Gotlinger, M. Kessler, L. G. Mendelowitz, J. R. Falck, A. S. Arbab, A. G. Scicli, M. L. Schwartzman, J. Yang and A. M. Guo: 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther 348, 442-51 (2014)
- [188] S. Lu, C. Zhu, A. Long, L. Tan, Q. Li and Y. Zhu: Effect of 20-hydroxyeicosatetraenoic acid on biological behavior of human villous trophoblasts and uterine vascular smooth muscle cells. Mol Med Rep 9, 1889-94 (2014)
- [189] Z. Wang, X. Tang, Y. Li, C. Leu, L. Guo, X. Zheng and D. Zhu: 20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. Eur J Pharmacol 588, 9-17 (2008)
- [190] G. L. Baumbach and D. D. Heistad: Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13, 968-72 (1989)
- [191] R. D. Levere, P. Martasek, B. Escalante, M. L. Schwartzman and N. G. Abraham: Effect of heme arginate administration on bloodhttp://dx.doi.org/10.1172/JCI114686 pressure in spontaneously hypertensive rats. J Clin Invest 86, 213-9 (1990)
- [192] M. L. Schwartzman, K. Omata, F. M. Lin, R. K. Bhatt, J. R. Falck and N. G. Abraham: Detection of 20-hydroxyeicosatetraenoic acid in rat urine. Biochem Biophys Res Commun 180, 445-9 (1991)
- [193] D. Gebremedhin, Y. H. Ma, J. D. Imig, D. R. Harder and R. J. Roman: Role of cytochrome P-450 in elevating renal vascular tone in spontaneously hypertensive rats. J Vasc Res 30, 53-60 (1993)
- [194] J. C. Frisbee, R. J. Roman, J. R. Falck, J. R. Linderman and J. H. Lombard: Impairment of flow-induced dilation of skeletal muscle arterioles with elevated oxygen in normotensive and hypertensive rats. Microvasc Res 60, 37-48 (2000)
- [195] Y. Ding, C. C. Wu, V. Garcia, I. Dimitrova, A. Weidenhammer, G. Joseph, F. Zhang, V. L. Manthati, J. R. Falck, J. H. Capdevila and M. L. Schwartzman: 20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension. Am J Physiol Renal Physiol 305, F753-63 (2013)
- [196] V. Garcia, G. Joseph, B. Shkolnik, Y. Ding, F. F. Zhang, K. Gotlinger, J. R. Falck, R. Dakarapu, J. H. Capdevila, K. E. Bernstein and M. L. Schwartzman: Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 309, R71-8 (2015)
- [197] F. Ljuca and G. Drevensek: Endothelin-1 induced vascular smooth muscle cell proliferation is mediated by cytochrome p-450 arachidonic acid metabolites. Bosn J Basic Med Sci 10, 223-6 (2010)
- [198] L. Chen, R. Ackerman and A. M. Guo: 20-HETE in neovascularization. Prostaglandins Other Lipid Mediat 98, 63-8 (2012) do
- [199] M. B. Sewer, D. R. Koop and E. T. Morgan: Endotoxemia in rats is associated with induction of the P450 4A subfamily and suppression of several other forms of cytochrome P450. Drug Metab Dispos 24, 401-7 (1996)
- [200] F. A. Yaghini, C. Zhang, J. H. Parmentier, A. M. Estes, N. Jafari, S. A. Schaefer and K. U. Malik: Contribution of arachidonic acid metabolites derived via cytochrome P450 4A to angiotensin II-induced neointimal growth. Hypertension 45, 1182-7 (2005)
- [201] G. Sa, G. Murugesan, M. Jaye, Y. Ivashchenko and P. L. Fox: Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem 270, 2360-6 (1995)
- [202] S. L. Amaral, K. G. Maier, D. N. Schippers, R. J. Roman and A. S. Greene: CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 284, H1528-35 (2003)
- [203] M. Jiang, A. Mezentsev, R. Kemp, K. Byun, J. R. Falck, J. M. Miano, A. Nasjletti, N. G. Abraham and M. Laniado-Schwartzman: Smooth muscle--specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res 94, 167-74 (2004)
- [204] P. Chen, M. Guo, D. Wygle, P. A. Edwards, J. R. Falck, R. J. Roman and A. G. Scicli: Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166, 615-24 (2005)
- [205] A. Dhanasekaran, S. Bodiga, S. Gruenloh, Y. Gao, L. Dunn, J. R. Falck, J. N. Buonaccorsi, M. Medhora and E. R. Jacobs: 20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells. Am J Physiol Heart Circ Physiol 296, H777-86 (2009)
- [206] T. F. Borin, D. A. Zuccari, B. V. Jardim-Perassi, L. C. Ferreira, A. S. Iskander, N. R. Varma, A. Shankar, A. M. Guo, G. Scicli and A. S. Arbab: HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice. PLoS One 9, e116247 (2014)
- [207] W. Yu, L. Chen, Y. Q. Yang, J. R. Falck, A. M. Guo, Y. Li and J. Yang: Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol 68, 619-29 (2011)
- [208] M. Guo, R. J. Roman, J. D. Fenstermacher, S. L. Brown, J. R. Falck, A. S. Arbab, P. A. Edwards and A. G. Scicli: 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N’-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317, 97-108 (2006)
- [209] M. Guo, R. J. Roman, J. R. Falck, P. A. Edwards and A. G. Scicli: Human U251 glioma cell proliferation is suppressed by HET0016 (N-hydroxy-N’-(4-butyl-2-methylphenyl)formamidine), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315, 526-33 (2005)
- [210] A. M. Guo, J. Sheng, G. M. Scicli, A. S. Arbab, N. L. Lehman, P. A. Edwards, J. R. Falck, R. J. Roman and A. G. Scicli: Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. J Pharmacol Exp Ther 327, 10-9 (2008)
- [211] A. Alexanian, B. Miller, R. J. Roman and A. Sorokin: 20-HETE-producing enzymes are up-regulated in human cancers. Cancer Genomics Proteomics 9, 163-9 (2012)
- [212] N. Mozzillo, E. Pennacchioli, S. Gandini, C. Caraco, A. Crispo, G. Botti, S. Lastoria, M. Barberis, F. Verrecchia and A. Testori: Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol 20, 2780-6 (2013)
- [213] A. Alexanian and A. Sorokin: Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potential. Onco Targets Ther 6, 243-55 (2013)
- [214] A. L. Johnson, K. Z. Edson, R. A. Totah and A. E. Rettie: Cytochrome P450 omega-Hydroxylases in Inflammation and Cancer. Adv Pharmacol 74, 223-62 (2015)
- [215] X. Y. Yu, C. S. Glantz, J. Yao, H. He, A. J. Petrocchi, D. K. Craig, J. T. Ciolek and A. E. Booth: Enhancing the chemical mixture methodology in emergency preparedness and consequence assessment analysis. Toxicology 313, 174-84 (2013)
- [216] D. Panigrahy, A. Kaipainen, E. R. Greene and S. Huang: Cytochrome P450-derived eicosanoids: the neglected pathway in can
- [217] Y. Zhang, M. N. Hoda, X. Zheng, W. Li, P. Luo, K. R. Maddipati, T. Seki, A. Ergul and M. H. Wang: Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition. Am J Physiol Regul Integr Comp Physiol 307, R693-703 (2014)
- [218] M. M. Bednar, C. E. Gross, M. K. Balazy, Y. Belosludtsev, D. T. Colella, J. R. Falck and M. Balazy: 16(R)-hydroxy-5,8,11,14-eicosatetraenoic acid, a new arachidonate metabolite in human polymorphonuclear leukocytes. Biochem Pharmacol 60, 447-55 (2000)
- [219] M. Rosolowsky, J. R. Falck and W. B. Campbell: Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Biochim Biophys Acta 1300, 143-50 (1996)
- [220] Y. Zhu, E. B. Schieber, J. C. McGiff and M. Balazy: Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25, 854-9 (1995)
- [221] J. Y. Liu, N. Li, J. Yang, N. Li, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu and B. D. Hammock: Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A 107, 17017-22 (2010)
- [222] C. L. Bos, D. J. Richel, T. Ritsema, M. P. Peppelenbosch and H. H. Versteeg: Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36, 1187-205 (2004)
- [223] O. Kowal-Bielecka, K. Kowal, O. Distler, J. Rojewska, A. Bodzenta-Lukaszyk, B. A. Michel, R. E. Gay, S. Gay and S. Sierakowski: Cyclooxygenase-and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 52, 3783-91 (2005)
- [224] N. Sehgal, V. Agarwal, R. K. Valli, S. D. Joshi, L. Antonovic, H. W. Strobel and V. Ravindranath: Cytochrome P450 4f, a potential therapeutic target limiting neuroinflammation. Biochem Pharmacol 82, 53-64 (2011)
- [225] Y. Wang, J. Zhao, A. Kalsotra, C. M. Turman, R. J. Grill, P. K. Dash and H. W. Strobel: CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury. J Neurotrauma 25, 1187-94 (2008)
- [226] X. Liu, P. Zhu and B. D. Freedman: Multiple eicosanoid-activated nonselective cation channels regulate B-lymphocyte adhesion to integrin ligands. Am J Physiol Cell Physiol 290, C873-82 (2006)
- [227] B. Tunctan, B. Korkmaz, A. N. Sari, M. Kacan, D. Unsal, M. S. Serin, C. K. Buharalioglu, S. Sahan-Firat, T. Cuez, W. H. Schunck, V. L. Manthati, J. R. Falck and K. U. Malik: Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock. Nitric Oxide 33, 18-41 (2013)
- [228] B. Tunctan, B. Korkmaz, A. N. Sari, M. Kacan, D. Unsal, M. S. Serin, C. K. Buharalioglu, S. Sahan-Firat, T. Cuez, W. H. Schunck, J. R. Falck and K. U. Malik: 5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKKbeta/IkappaB-alpha/NF-kappaB pathway, and proinflammatory cytokine formation. Prostaglandins Other Lipid Mediat 102-103, 31-41 (2013)
- [229] C. W. Sun, M. Alonso-Galicia, M. R. Taheri, J. R. Falck, D. R. Harder and R. J. Roman: Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ Res 83, 1069-79 (1998)
- [230] M. Alonso-Galicia, A. G. Hudetz, H. Shen, D. R. Harder and R. J. Roman: Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke 30, 2727-34; discussion 2734 (1999)
- [231] M. H. Wang, J. Wang, H. H. Chang, B. A. Zand, M. Jiang, A. Nasjletti and M. Laniado-Schwartzman: Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. Am J Physiol Renal Physiol 285, F295-302 (2003)
- [232] U. Hoff, I. Lukitsch, L. Chaykovska, M. Ladwig, C. Arnold, V. L. Manthati, T. F. Fuller, W. Schneider, M. Gollasch, D. N. Muller, B. Flemming, E. Seeliger, F. C. Luft, J. R. Falck, D. Dragun and W. H. Schunck: Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int 79, 57-65 (2011)
- [233] D. L. Lee, J. L. Wilson, R. Duan, T. Hudson and A. El-Marakby: Peroxisome Proliferator-Activated Receptor-alpha Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension. PPAR Res 502631 (2011)
- [234] P. Zhu, X. Liu, E. F. Labelle and B. D. Freedman: Mechanisms of hypotonicity-induced calcium signaling and integrin activation by arachidonic acid-derived inflammatory mediators in B cells. J Immunol 175, 4981-9 (2005)
- [235] J. P. Broderick, T. G. Brott, J. E. Duldner, T. Tomsick and A. Leach: Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 25, 1342-7 (1994)
- [236] J. W. Hop, G. J. Rinkel, A. Algra and J. van Gijn: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 28, 660-4 (1997)
- [237] H. P. Adams, Jr., N. F. Kassell, J. C. Torner, D. W. Nibbelink and A. L. Sahs: Early management of aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 54, 141-5 (1981)
- [238] H. L. Tian, Z. Geng, Y. H. Cui, J. Hu, T. Xu, H. L. Cao, S. W. Chen and H. Chen: Risk factors for posttraumatic cerebral infarction in patients with moderate or severe head trauma. Neurosurg Rev 31, 431-6; discussion 436-7 (2008)
- [239] I. Tawil, D. M. Stein, S. E. Mirvis and T. M. Scalea: Posttraumatic cerebral infarction: incidence, outcome, and risk factors. J Trauma 64, 849-53 (2008)
- [240] M. D. Vergouwen, D. Ilodigwe and R. L. Macdonald: Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 42, 924-9 (2011)
- [241] B. Weir, M. Grace, J. Hansen and C. Rothberg: Time course of vasospasm in man. J Neurosurg 48, 173-8 (1978)
- [242] J. F. Megyesi, B. Vollrath, D. A. Cook and J. M. Findlay: In vivo animal models of cerebral vasospasm: a review. Neurosurgery 46, 448-60 (2000)
- [243] C. G. Sobey and F. M. Faraci: Subarachnoid haemorrhage: what happens to the cerebral arteries? Clin Exp Pharmacol Physiol 25, 867-76 (1998)
- [244] J. B. Bederson, A. L. Levy, W. H. Ding, R. Kahn, C. A. DiPerna, A. L. Jenkins, 3rd and P. Vallabhajosyula: Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 42, 352-60 (1998)
- [245] R. L. Macdonald and B. K. Weir: A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 22, 971-82 (1991)
- [246] R. M. Pluta, J. K. Afshar, R. J. Boock and E. H. Oldfield: Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. J Neurosurg 88, 557-61 (1998)
- [247] R. L. Macdonald, B. K. Weir, L. S. Marton, Z. D. Zhang, M. Sajdak, L. M. Johns, A. Kowalczuk and M. Borsody: Role of adenosine 5’-triphosphate in vasospasm after subarachnoid hemorrhage: human investigations. Neurosurgery 48, 854-62; (2001)
- [248] W. M. Armstead: Endothelins and the role of endothelin antagonists in the management of posttraumatic vasospasm. Curr Pharm Des 10, 2185-92 (2004)
- [249] S. Juvela: Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 92, 390-400 (2000)
- [250] S. W. Hoffman, B. A. Rzigalinski, K. A. Willoughby and E. F. Ellis: Astrocytes generate isoprostanes in response to trauma or oxygen radicals. J Neurotrauma 17, 415-20 (2000)
- [251] S. W. Hoffman, S. Moore and E. F. Ellis: Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 28, 844-9 (1997)
- [252] L. Cambj-Sapunar, M. Yu, D. R. Harder and R. J. Roman: Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke 34, 1269-75 (2003)
- [253] D. R. Harder: Increased sensitivity of cat cerebral arteries to serotonin upon elevation of transmural pressure. Pflugers Arch 411, 698-700 (1988)
- [254] A. D. Mendelow, T. A. McCalden, J. Hattingh, A. Coull, C. Rosendorff and B. H. Eidelman: Cerebrovascular reactivity and metabolism after subarachnoid hemorrhage in baboons. Stroke 12, 58-65 (1981)
- [255] M. Clozel and H. Watanabe: BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 52, 825-34 (1993)
- [256] P. L. Foley, H. H. Caner, N. F. Kassell and K. S. Lee: Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 34, 108-12 (1994)
- [257] J. Josko, S. Hendryk, H. Jedrzejowska-Szypula, B. Gwozdz, Z. S. Herman and R. Gawlik: Influence endothelin ETA receptor antagonist--BQ-123--on changes of endothelin-1 level in plasma of rats with acute vasospasm following subarachnoid hemorrhage. J Physiol Pharmacol 49, 367-75 (1998)
- [258] M. Kaminogo, M. Yonekura, M. Onizuka, A. Yasunaga and S. Shibata: Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. Neurol Med Chir 38, 704-8 (1998)
- [259] H. Takeuchi, M. Tanabe, H. Okamoto and M. Yamazaki: Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm. Neurol Res 21, 513-6 (1999)
- [260] M. Yamaguchi, C. Zhou, A. Nanda and J. H. Zhang: Ras protein contributes to cerebral vasospasm in a canine double-hemorrhage model. Stroke 35, 1750-5 (2004)
- [261] G. Wickman, C. Lan and B. Vollrath: Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm. Circ Res 92, 809-16 (2003)
- [262] K. Obara, S. Nishizawa, M. Koide, K. Nozawa, A. Mitate, T. Ishikawa and K. Nakayama: Interactive role of protein kinase C-delta with rho-kinase in the development of cerebral vasospasm in a canine two-hemorrhage model. J Vasc Res 42, 67-76 (2005)
- [263] Y. Miyagi, R. C. Carpenter, T. Meguro, A. D. Parent and J. H. Zhang: Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 93, 471-6 (2000)
- [264] T. Sasaki, H. Kasuya, H. Onda, A. Sasahara, S. Goto, T. Hori and I. Inoue: Role of p38 mitogen-activated protein kinase on cerebral vasospasm after subarachnoid hemorrhage. Stroke 35, 1466-70 (2004)
- [265] I. Laher and J. H. Zhang: Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab 21, 887-906 (2001)
- [266] T. Matsui, M. Sugawa, H. Johshita, Y. Takuwa and T. Asano: Activation of the protein kinase C-mediated contractile system in canine basilar artery undergoing chronic vasospasm. Stroke 22, 1183-7 (1991)
- [267] G. Kusaka, H. Kimura, I. Kusaka, E. Perkins, A. Nanda and J. H. Zhang: Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 99, 383-90 (2003)
- [268] S. Nishizawa, S. Yamamoto and K. Uemura: Interrelation between protein kinase C and nitric oxide in the development of vasospasm after subarachnoid hemorrhage. Neurol Res 18, 89-95 (1996)
- [269] D. R. Harder, P. Dernbach and A. Waters: Possible cellular mechanism for cerebral vasospasm after experimental subarachnoid hemorrhage in the dog. J Clin Invest 80, 875-80 (1987)
- [270] M. A. Murray, F. M. Faraci and D. D. Heistad: Effect of protein kinase C inhibitors on endothelin-and vasopressin-induced constriction of the rat basilar artery. Am J Physiol 263H1643-9 (1992)
- [271] P. Kim, V. B. Schini, T. M. Sundt, Jr. and P. M. Vanhoutte: Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage. Circ Res 70, 248-56 (1992)
- [272] C. G. Sobey, D. D. Heistad and F. M. Faraci: Effect of subarachnoid hemorrhage on dilatation of rat basilar artery in vivo. Am J Physiol 271, H126-32 (1996)
- [273] S. Yamamoto, S. Nishizawa, T. Yokoyama, H. Ryu and K. Uemura: Subarachnoid hemorrhage impairs cerebral blood flow response to nitric oxide but not to cyclic GMP in large cerebral arteries. Brain Res 757, 1-9 (1997)
- [274] A. Y. Schwartz, F. A. Sehba and J. B. Bederson: Decreased nitric oxide availability contributes to acute cerebral ischemia after subarachnoid hemorrhage. Neurosurgery 47, 208-14 (2000)
- [275] S. M. Poloyac, R. B. Reynolds, H. Yonas and M. E. Kerr: Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J Neurosci Methods 144, 257-63 (2005)
- [276] M. K. Donnelly, E. A. Crago, Y. P. Conley, J. R. Balzer, D. Ren, A. F. Ducruet, P. M. Kochanek, P. R. Sherwood and S. M. Poloyac: 20-HETE is associated with unfavorable outcomes in subarachnoid hemorrhage patients. J Cereb Blood Flow Metab 35, 1515-22 (2015)
- [277] D. A. Siler, R. P. Martini, J. P. Ward, J. W. Nelson, R. N. Borkar, K. L. Zuloaga, J. J. Liu, S. L. Fairbanks, J. S. Raskin, V. C. Anderson, A. Dogan, R. K. Wang, N. J. Alkayed and J. S. Cetas: Protective role of p450 epoxyeicosanoids in subarachnoid hemorrhage. Neurocrit Care 22, 306-19 (2015)
- [278] J. G. Pilitsis, W. M. Coplin, M. H. O’Regan, J. M. Wellwood, F. G. Diaz, M. R. Fairfax, D. B. Michael and J. W. Phillis: Measurement of free fatty acids in cerebrospinal fluid from patients with hemorrhagic and ischemic stroke. Brain Res 985, 198-201 (2003)
- [279] K. Takeuchi, M. Renic, Q. C. Bohman, D. R. Harder, N. Miyata and R. J. Roman: Reversal of delayed vasospasm by an inhibitor of the synthesis of 20-HETE. Am J Physiol Heart Circ Physiol 289, H2203-11 (2005)
- [280] N. Miyata, T. Seki, Y. Tanaka, T. Omura, K. Taniguchi, M. Doi, K. Bandou, S. Kametani, M. Sato, S. Okuyama, L. Cambj-Sapunar, D. R. Harder and R. J. Roman: Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 (N-(3-chloro-4-morpholin-4-yl) phenyl-N’-hydroxyimido formamide), on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther 314, 77-85 (2005)
- [281] J. P. Dreier, S. Major, A. Manning, J. Woitzik, C. Drenckhahn, J. Steinbrink, C. Tolias, A. I. Oliveira-Ferreira, M. Fabricius, J. A. Hartings, P. Vajkoczy, M. Lauritzen, U. Dirnagl, G. Bohner, A. J. Strong and C. s. group: Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 132, 1866-81 (2009)
- [282] J. C. Fordsmann, R. W. Ko, H. B. Choi, K. Thomsen, B. M. Witgen, C. Mathiesen, M. Lonstrup, H. Piilgaard, B. A. MacVicar and M. Lauritzen: Increased 20-HETE synthesis explains reduced cerebral blood flow but not impaired neurovascular coupling after cortical spreading depression in rat cerebral cortex. J Neurosci 33, 2562-70 (2013)
- [283] J. S. Shaik, S. M. Poloyac, P. M. Kochanek, H. Alexander, D. L. Tudorascu, R. S. Clark and M. D. Manole: 20-Hydroxyeicosatetraenoic Acid Inhibition by HET0016 Offers Neuroprotection, Decreases Edema, and Increases Cortical Cerebral Blood Flow in a Pediatric Asphyxial Cardiac Arrest Model in Rats. J Cereb Blood Flow Metab 35, 1757-63 (2015)
- [284] G. E. Cold: Cerebral blood flow in the acute phase after head injury. Part 2: Correlation to intraventricular pressure (IVP), cerebral perfusion pressure (CPP), PaCO2, ventricular fluid lactate, lactate/pyruvate ratio and pH. Acta Anaesthesiol Scand 25, 332-5 (1981)
- [285] G. E. Cold and F. T. Jensen: Cerebral autoregulation in unconscious patients with brain injury. Acta Anaesthesiol Scand 22, 270-80 (1978)
- [286] J. Overgaard and W. A. Tweed: Cerebral circulation after head injury. 1. Cerebral blood flow and its regulation after closed head injury with emphasis on clinical correlations. J Neurosurg 41, 531-41 (1974)
- [287] O. B. Paulson, S. Strandgaard and L. Edvinsson: Cerebral autoregulation. Cerebrovasc Brain Metab Rev 2, 161-92 (1990)
- [288] A. J. Strong, M. Fabricius, M. G. Boutelle, S. J. Hibbins, S. E. Hopwood, R. Jones, M. C. Parkin and M. Lauritzen: Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33, 2738-43 (2002)
- [289] M. Hiler, M. Czosnyka, P. Hutchinson, M. Balestreri, P. Smielewski, B. Matta and J. D. Pickard: Predictive value of initial computerized tomography scan, intracranial pressure, and state of autoregulation in patients with traumatic brain injury. J Neurosurg 104, 731-7 (2006)
- [290] E. A. Schmidt, M. Czosnyka, L. A. Steiner, M. Balestreri, P. Smielewski, S. K. Piechnik, B. F. Matta and J. D. Pickard: Asymmetry of pressure autoregulation after traumatic brain injury. J Neurosurg 99, 991-8 (2003)
- [291] L. A. Steiner, M. Czosnyka, S. K. Piechnik, P. Smielewski, D. Chatfield, D. K. Menon and J. D. Pickard: Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med 30, 733-8 (2002)
- [292] K. M. Brady, D. H. Shaffner, J. K. Lee, R. B. Easley, P. Smielewski, M. Czosnyka, G. I. Jallo and A. M. Guerguerian: Continuous monitoring of cerebrovascular pressure reactivity after traumatic brain injury in children. Pediatrics 124, e1205-12 (2009)
- [293] E. P. Wei, R. G. Lamb and H. A. Kontos: Increased phospholipase C activity after experimental brain injury. J Neurosurg 56, 695-8 (1982)
- [294] P. Homayoun, E. B. Rodriguez de Turco, N. E. Parkins, D. C. Lane, J. Soblosky, M. E. Carey and N. G. Bazan: Delayed phospholipid degradation in rat brain after traumatic brain injury. J Neurochem 69, 199-205 (1997)
- [295] J. W. Phillis and M. H. O’Regan: A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Brain Res Rev 44, 13-47 (2004)
- [296] J. G. Pilitsis, W. M. Coplin, M. H. O’Regan, J. M. Wellwood, F. G. Diaz, M. R. Fairfax, D. B. Michael and J. W. Phillis: Free fatty acids in cerebrospinal fluids from patients with traumatic brain injury. Neurosci Lett 349, 136-8 (2003)
- [297] M. Birnie, R. Morrison, R. Camara and K. I. Strauss: Temporal changes of cytochrome P450 (Cyp) and eicosanoid-related gene expression in the rat brain after traumatic brain injury. BMC Genomics 14, 303 (2013)
- [298] G. Stoll, C. Kleinschnitz and B. Nieswandt: Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112, 3555-62 (2008)
- [299] M. D. Ginsberg: Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 34, 214-23 (2003)
- [300] S. T. Carmichael: Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2, 396-409 (2005)
- [301] K. A. Hossmann: Experimental models for the investigation of brain ischemia. Cardiovasc Res 39, 106-20 (1998)
- [302] J. Folbergrova, H. Memezawa, M. L. Smith and B. K. Siesjo: Focal and perifocal changes in tissue energy state during middle cerebral artery occlusion in normo-and hyperglycemic rats. J Cereb Blood Flow Metab 12, 25-33 (1992)
- [303] E. Sarvary, J. H. Halsey, K. A. Conger, J. H. Garcia and A. G. Kovach: ATP and pH predictors of histologic damage following global cerebral ischemia in the rat. Acta Physiol Hung 82, 109-24 (1994)
- [304] M. Chen, D. J. Won, S. Krajewski and R. A. Gottlieb: Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 277, 29181-6 (2002)
- [305] K. B. MacKay, T. R. Patel, S. L. Galbraith, G. N. Woodruff and J. McCulloch: The relationship between glutamate release and cerebral blood flow after focal cerebral ischaemia in the cat: effect of pretreatment with enadoline (a kappa receptor agonist). Brain Res 712, 329-34 (1996)
- [306] E. E. Tseng, M. V. Brock, C. C. Kwon, M. Annanata, M. S. Lange, J. C. Troncoso, M. V. Johnston and W. A. Baumgartner: Increased intracerebral excitatory amino acids and nitric oxide after hypothermic circulatory arrest. Ann Thorac Surg 67, 371-6 (1999)
- [307] L. L. Werling, H. M. Jacocks, 3rd, R. E. Rosenthal and G. Fiskum: Dopamine release from canine striatum following global cerebral ischemia/reperfusion. Brain Res 606, 99-105 (1993)
- [308] L. L. Guyot, F. G. Diaz, M. H. O’Regan, S. McLeod, H. Park and J. W. Phillis: Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett 299, 37-40 (2001)
- [309] F. Mauler, T. Fahrig, E. Horvath and R. Jork: Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Brain Res 888, 150-157 (2001)
- [310] J. G. Pilitsis, F. G. Diaz, M. H. O’Regan and J. W. Phillis: Differential effects of phospholipase inhibitors on free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res 951, 96-106 (2002)
- [311] K. Narita, M. Kubota, M. Nakane, S. Kitahara, T. Nakagomi, A. Tamura, H. Hisaki, H. Shimasaki and N. Ueta: Therapeutic time window in the penumbra during permanent focal ischemia in rats: changes of free fatty acids and glycerophospholipids. Neurol Res 22, 393-400 (2000)
- [312] D. Sun, D. Kintner, J. H. Fitzpatrick, S. E. Emoto, P. G. Braquet, N. G. Bazan and D. D. Gilboe: The effect of a free radical scavenger and platelet-activating factor antagonist on FFA accumulation in post-ischemic canine brain. Neurochem Res 19, 525-8 (1994)
- [313] Y. Liu, S. Mituska, K. Hashizume, T. Hosaka and H. Nukui: The time course of glucose metabolism in rat cerebral ischemia with middle cerebral artery occlusion-reperfusion model and the effect of MK-801. Neurol Res, 18(6), 505-8 (1996)
- [314] E. D. Hall: Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci 134, 79-83 (1995)
- [315] R. Murin, A. Drgova, P. Kaplan, D. Dobrota and J. Lehotsky: Ischemia/Reperfusion-induced oxidative stress causes structural changes of brain membrane proteins and lipids. Gen Physiol Biophys 20, 431-8 (2001)
- [316] E. McCracken, V. Valeriani, C. Simpson, T. Jover, J. McCulloch and D. Dewar: The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. J Cereb Blood Flow Metab 20, 1529-36 (2000)
- [317] P. Ciceri, M. Rabuffetti, A. Monopoli and S. Nicosia: Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br J Pharmacol 133, 1323-9 (2001)
- [318] F. Tegtmeier, C. Weber, U. Heister, I. Haker, D. Scheller, R. Nikolov and M. Holler: Eicosanoids in rat brain during ischemia and reperfusion--correlation to DC depolarization. J Cereb Blood Flow Metab 10, 358-64 (1990)
- [319] M. Usui, T. Asano and K. Takakura: Identification and quantitative analysis of hydroxy-eicosatetraenoic acids in rat brains exposed to regional ischemia. Stroke 18, 490-4 (1987)
- [320] Y. Tanaka, T. Omura, M. Fukasawa, N. Horiuchi, N. Miyata, T. Minagawa, S. Yoshida and S. Nakaike: Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. Neurosci Res 59, 475-80 (2007)
- [321] N. C. Ward, K. D. Croft, D. Blacker, G. J. Hankey, A. Barden, T. A. Mori, I. B. Puddey and C. D. Beer: Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci 121, 501-7 (2011)
- [322] Y. Tanaka, C. Koizumi, T. Tashiro, T. Susumu, M. Fukasawa, N. Horiuchi, T. Minagawa, T. Omura, N. Miyata and S. Yoshida: TS-011 improves neurological and functional outcomes after focal cerebral ischemia in rats. Stroke, (2007)
- [323] T. Marumo, K. Eto, H. Wake, T. Omura and J. Nabekura: The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br J Pharmacol 161, 1391-402 (2010)
- [324] S. M. Poloyac, Y. Zhang, R. R. Bies, P. M. Kochanek and S. H. Graham: Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J Cereb Blood Flow Metab 26, 1551-61 (2006)
- [325] V. Randriamboavonjy, R. Busse and I. Fleming: 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 41, 801-6 (2003)
- [326] C. W. Sun, J. R. Falck, D. R. Harder and R. J. Roman: Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33, 414-8 (1999)
- [327] M. M. Muthalif, I. F. Benter, Z. Khandekar, L. Gaber, A. Estes, S. Malik, J. H. Parmentier, V. Manne and K. U. Malik: Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension 35, 457-63 (2000)
- [328] M. M. Muthalif, N. A. Karzoun, L. Gaber, Z. Khandekar, I. F. Benter, A. E. Saeed, J. H. Parmentier, A. Estes and K. U. Malik: Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 36, 604-9 (2000)
- [329] M. M. Muthalif, M. R. Uddin, S. Fatima, J. Parmentier, Z. Khandekar and K. U. Malik: Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells(1). Prostaglandins 65, 33-43 (2001)
- [330] S. Nowicki, S. L. Chen, O. Aizman, X. J. Cheng, D. Li, C. Nowicki, A. Nairn, P. Greengard and A. Aperia: 20-Hydroxyeicosa-tetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+-ATPase. J Clin Invest 99, 1224-30 (1997)
- [331] G. M. Chertow, E. Burdick, M. Honour, J. V. Bonventre and D. W. Bates: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16, 3365-70 (2005)
- [332] N. Lameire, W. Van Biesen and R. Vanholder: The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2, 364-77 (2006)
- [333] N. Lameire and R. Vanholder: Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol 12 Suppl 17, S20-32 (2001)
- [334] K. Nithipatikom, E. R. Gross, M. P. Endsley, J. M. Moore, M. A. Isbell, J. R. Falck, W. B. Campbell and G. J. Gross: Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res 95, e65-71 (2004)
- [335] R. J. Roman, T. Akbulut, F. Park and K. R. Regner: 20-HETE in acute kidney injury. Kidney Int 79, 10-3 (2011)
- [336] J. M. Williams, A. Sarkis, K. M. Hoagland, K. Fredrich, R. P. Ryan, C. Moreno, B. Lopez, J. Lazar, F. J. Fenoy, M. Sharma, M. R. Garrett, H. J. Jacob and R. J. Roman: Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol 295, F1764-77 (2008)
- [337] D. P. Basile, D. Donohoe, X. Cao and S. K. Van Why: Resistance to ischemic acute renal failure in the Brown Norway rat: a new model to study cytoprotection. Kidney Int 65, 2201-11 (2004)
- [338] V. Nilakantan, C. Maenpaa, G. Jia, R. J. Roman and F. Park: 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 294, F562-70 (2008)
- [339] A. O. Oyekan: Differential effects of 20-hydroxyeicosatetraenoic acid on intrarenal blood flow in the rat. J Pharmacol Exp Ther 313, 1289-95 (2005)
- [340] T. Akbulut, K. R. Regner, R. J. Roman, E. D. Avner, J. R. Falck and F. Park: 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR-and c-Src-dependent mechanism. Am J Physiol 297, F662-F670 (2009)
- [341] J. F. di Mari, R. Davis and R. L. Safirstein: MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol 277, F195-203 (1999)
- [342] K. M. Park, A. Chen and J. V. Bonventre: Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem 276, 11870-6 (2001)
- [343] H. L. Waller, S. J. Harper, S. A. Hosgood, A. Bagul, M. D. Kay, M. Kaushik, B. Yang, G. R. Bicknell and M. L. Nicholson: Differential expression of cytoprotective and apoptotic genes in an ischaemia-reperfusion isolated organ perfusion model of the transplanted kidney. Transpl Int 20, 625-31 (2007)
- [344] J. Pratschke, S. Weiss, P. Neuhaus and A. Pascher: Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transpl Int 21, 512-22 (2008)
- [345] L. H. Toledo-Pereyra, A. H. Toledo, J. Walsh and F. Lopez-Neblina: Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant 2, 174-7 (2004)
- [346] D. Hernandez, S. Estupinan, G. Perez, M. Rufino, J. M. Gonzalez-Posada, D. Luis, P. Delgado, A. Rodriguez, D. Marrero, E. Porrini and A. Torres: Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transpl Int 21, 955-62 (2008)
- [347] A. S. Weiss, J. Gralla, L. Chan, P. Klem and A. C. Wiseman: Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol 3, 1812-9 (2008)
- [348] B. Dolegowska, W. Blogowski and L. Domanski: Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report. Transpl Int 22, 546-53 (2009)
- [349] B. Dolegowska, W. Blogowski, K. Safranow, L. Domanski, K. Jakubowska and M. Olszewska: Lipoxygenase-derived hydroxyeicosatetraenoic acids--novel perioperative markers of early post-transplant allograft function? Nephrol Dial Transplant 25, 4061-7 (2010)
- [350] E. R. Gross, K. Nithipatikom, A. K. Hsu, J. N. Peart, J. R. Falck, W. B. Campbell and G. J. Gross: Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol 37, 1245-9 (2004)
- [351] K. Nithipatikom, R. F. DiCamelli, S. Kohler, R. J. Gumina, J. R. Falck, W. B. Campbell and G. J. Gross: Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem 292, 115-24 (2001)
- [352] K. Nithipatikom, M. P. Endsley, J. M. Moore, M. A. Isbell, J. R. Falck, W. B. Campbell and G. J. Gross: Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol 290, H500-5 (2006)
- [353] Y. Bao, X. Wang, W. Li, D. Huo, X. Shen, Y. Han, J. Tan, Q. Zeng and C. Sun: 20-Hydroxyeicosatetraenoic acid induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways. J Cardiovasc Pharmacol 57, 294-301 (2011)
- [354] D. Mozaffarian, E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha, M. Cushman, S. de Ferranti, J. P. Despres, H. J. Fullerton, V. J. Howard, M. D. Huffman, S. E. Judd, B. M. Kissela, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, S. Liu, R. H. Mackey, D. B. Matchar, D. K. McGuire, E. R. Mohler, 3rd, C. S. Moy, P. Muntner, M. E. Mussolino, K. Nasir, R. W. Neumar, G. Nichol, L. Palaniappan, D. K. Pandey, M. J. Reeves, C. J. Rodriguez, P. D. Sorlie, J. Stein, A. Towfighi, T. N. Turan, S. S. Virani, J. Z. Willey, D. Woo, R. W. Yeh, M. B. Turner, C. American Heart Association Statistics and S. Stroke Statistics: Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 131, e29-322 (2015)
- [355] B. N. Zordoky, M. E. Aboutabl and A. O. El-Kadi: Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos 36, 2277-86 (2008)
- [356] H. N. Althurwi, O. H. Elshenawy and A. O. El-Kadi: Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol 63, 167-77 (2014)
- [357] M. E. Aboutabl, B. N. Zordoky, B. D. Hammock and A. O. El-Kadi: Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J Cardiovasc Pharmacol 57, 273-81 (2011)
- [358] M. E. Aboutabl, B. N. Zordoky and A. O. El-Kadi: 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158, 1808-19 (2009)
- [359] S. Elkhatali, A. A. El-Sherbeni, O. H. Elshenawy, G. Abdelhamid and A. O. El-Kadi: 19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy. Toxicol Appl Pharmacol 289, 550-9 (2015)
- [360] B. N. Zordoky and A. O. El-Kadi: Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 9, 122-8 (2008)
- [361] B. N. Zordoky, A. Anwar-Mohamed, M. E. Aboutabl and A. O. El-Kadi: Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242, 38-46 (2010)
- [362] Q. Zeng, Y. Han, Y. Bao, W. Li, X. Li, X. Shen, X. Wang, F. Yao, S. T. O’Rourke and C. Sun: 20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type Ca2+ channel via a PKC-dependent mechanism in cardiomyocytes. Am J Physiol Heart Circ Physiol 299, H1109-17 (2010)
- [363] M. U. Moreno, G. San Jose, A. Pejenaute, M. F. Landecho, J. Diez, O. Beloqui, A. Fortuno and G. Zalba: Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1? Hypertension 63, 468-74 (2014)
- [364] S. F. Steinberg: Cardiac actions of protein kinase C isoforms. Physiology 27, 130-9 (2012)
- [365] G. W. Dorn, 2nd and T. Force: Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115, 527-37 (2005)
- [366] T. Shinomura, Y. Asaoka, M. Oka, K. Yoshida and Y. Nishizuka: Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. Proc Natl Acad Sci U S A 88, 5149-53 (1991)
- [367] H. Zhao, G. Qi, Y. Han, X. Shen, F. Yao, C. Xuan, Y. Gu, S. Y. Qian, Q. Zeng, S. T. O’Rourke and C. Sun: 20-Hydroxyeicosatetraenoic Acid Is a Key Mediator of Angiotensin II-induced Apoptosis in Cardiac Myocytes. J Cardiovasc Pharmacol 66, 86-95 (2015)